<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>exh_21.htm
<DESCRIPTION>EXHIBIT 2.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>EXHIBIT 2.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<DIV STYLE="padding: 0in 0in 1pt; border-bottom: Black 4.5pt double">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">EXECUTION VERSION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>[*****] Text omitted for confidential treatment.
The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly
disclosed.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><I>&nbsp;</I></P>


</DIV>


<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps; text-transform: uppercase">Asset
Purchase Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps; text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps; text-transform: uppercase"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Dated as of December 7, 2019</P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: normal">between</FONT></P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: normal; text-transform: uppercase">JANSSEN
BIOTECH, INC.</FONT></P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: normal">and</FONT></P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: normal">&nbsp;</FONT></P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: normal"><FONT STYLE="text-transform: uppercase">XBIOTECH
INC.</FONT></FONT></P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: normal"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></FONT></P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: normal"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></FONT></P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: normal"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></FONT></P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: normal"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></FONT></P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: normal"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></FONT></P>

<DIV STYLE="padding: 0in 0in 1pt; border-bottom: Black 4.5pt double">
<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: normal"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></FONT></P>
</div>
<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: normal"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U></U></B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>TABLE OF CONTENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B><U>Page</U></B></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="4" STYLE="text-align: center">ARTICLE I</TD></TR>
<TR>
    <TD STYLE="vertical-align: middle; text-align: center; width: 12%; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 81%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 5%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="4" STYLE="text-align: center">Definitions; Interpretation</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="4" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 1.1.</TD>
    <TD>&nbsp;</TD>
    <TD>Definitions</TD>
    <TD STYLE="text-align: right">1</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 1.2.</TD>
    <TD>&nbsp;</TD>
    <TD>Interpretation</TD>
    <TD STYLE="text-align: right">12</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="4" STYLE="text-align: center">ARTICLE II</TD></TR>
<TR>
    <TD STYLE="vertical-align: middle; text-align: center; white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="4" STYLE="text-align: center">Purchase and Sale</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="4" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 2.1.</TD>
    <TD>&nbsp;</TD>
    <TD>Purchase and Sale of Purchased Assets; Purchase Price</TD>
    <TD STYLE="text-align: right">13</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 2.2.</TD>
    <TD>&nbsp;</TD>
    <TD>Purchased Assets; Excluded Assets</TD>
    <TD STYLE="text-align: right">13</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 2.3.</TD>
    <TD>&nbsp;</TD>
    <TD>Assumed Liabilities; Excluded Liabilities</TD>
    <TD STYLE="text-align: right">15</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 2.4.</TD>
    <TD>&nbsp;</TD>
    <TD>Closing; Closing Deliverables</TD>
    <TD STYLE="text-align: right">16</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 2.5.</TD>
    <TD>&nbsp;</TD>
    <TD>Milestone Payments</TD>
    <TD STYLE="text-align: right">18</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 2.6.</TD>
    <TD>&nbsp;</TD>
    <TD>Third Party Consents</TD>
    <TD STYLE="text-align: right">19</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 2.7.</TD>
    <TD>&nbsp;</TD>
    <TD>Escrow Amount</TD>
    <TD STYLE="text-align: right">20</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="4" STYLE="text-align: center">ARTICLE III</TD></TR>
<TR>
    <TD STYLE="vertical-align: middle; text-align: center; white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="4" STYLE="text-align: center">Representations and Warranties of Seller</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="4" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 3.1.</TD>
    <TD>&nbsp;</TD>
    <TD>Organization, Standing and Power</TD>
    <TD STYLE="text-align: right">20</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 3.2.</TD>
    <TD>&nbsp;</TD>
    <TD>Authority; Noncontravention</TD>
    <TD STYLE="text-align: right">21</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 3.3.</TD>
    <TD>&nbsp;</TD>
    <TD>Absence of Certain Changes or Events</TD>
    <TD STYLE="text-align: right">22</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 3.4.</TD>
    <TD>&nbsp;</TD>
    <TD>Good Title; Sufficiency of Assets</TD>
    <TD STYLE="text-align: right">22</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 3.5.</TD>
    <TD>&nbsp;</TD>
    <TD>Intellectual Property</TD>
    <TD STYLE="text-align: right">22</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 3.6.</TD>
    <TD>&nbsp;</TD>
    <TD>Assumed Contracts</TD>
    <TD STYLE="text-align: right">26</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 3.7.</TD>
    <TD>&nbsp;</TD>
    <TD>Compliance with Law; Permits</TD>
    <TD STYLE="text-align: right">26</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 3.8.</TD>
    <TD>&nbsp;</TD>
    <TD>Litigation</TD>
    <TD STYLE="text-align: right">27</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 3.9.</TD>
    <TD>&nbsp;</TD>
    <TD>Taxes</TD>
    <TD STYLE="text-align: right">27</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 3.10.</TD>
    <TD>&nbsp;</TD>
    <TD>Employees and Employee Benefit Plans; Labor Relations</TD>
    <TD STYLE="text-align: right">28</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 3.11.</TD>
    <TD>&nbsp;</TD>
    <TD>Regulatory Matters</TD>
    <TD STYLE="text-align: right">29</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 3.12.</TD>
    <TD>&nbsp;</TD>
    <TD>Inventory</TD>
    <TD STYLE="text-align: right">32</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 3.13.</TD>
    <TD>&nbsp;</TD>
    <TD>Relationships with Suppliers</TD>
    <TD STYLE="text-align: right">32</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 3.14.</TD>
    <TD>&nbsp;</TD>
    <TD>Brokers and Other Advisors</TD>
    <TD STYLE="text-align: right">32</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 3.15.</TD>
    <TD>&nbsp;</TD>
    <TD>Insurance</TD>
    <TD STYLE="text-align: right">32</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 3.16.</TD>
    <TD>&nbsp;</TD>
    <TD>Adequate Consideration; Continued Solvency</TD>
    <TD STYLE="text-align: right">32</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 3.17.</TD>
    <TD>&nbsp;</TD>
    <TD>Related Party Transactions</TD>
    <TD STYLE="text-align: right">32</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 12%; white-space: nowrap">Section 3.18.</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 81%">Anticorruption Matters</TD>
    <TD STYLE="text-align: right; width: 5%">33</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 3.19.</TD>
    <TD>&nbsp;</TD>
    <TD>Export Controls and Sanctions Matters</TD>
    <TD STYLE="text-align: right">33</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 3.20.</TD>
    <TD>&nbsp;</TD>
    <TD>No Other Representations and Warranties</TD>
    <TD STYLE="text-align: right">34</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="4" STYLE="text-align: center">ARTICLE IV</TD></TR>
<TR>
    <TD STYLE="vertical-align: middle; text-align: center; white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="4" STYLE="text-align: center">Representations and Warranties of Buyer</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="4" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 4.1.</TD>
    <TD>&nbsp;</TD>
    <TD>Organization, Standing and Power</TD>
    <TD STYLE="text-align: right">35</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 4.2.</TD>
    <TD>&nbsp;</TD>
    <TD>Authority; Noncontravention</TD>
    <TD STYLE="text-align: right">35</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 4.3.</TD>
    <TD>&nbsp;</TD>
    <TD>Capital Resources</TD>
    <TD STYLE="text-align: right">36</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 4.4.</TD>
    <TD>&nbsp;</TD>
    <TD>Litigation</TD>
    <TD STYLE="text-align: right">36</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 4.5.</TD>
    <TD>&nbsp;</TD>
    <TD>Brokers and Other Advisors</TD>
    <TD STYLE="text-align: right">36</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 4.6.</TD>
    <TD>&nbsp;</TD>
    <TD>Independent Investigation</TD>
    <TD STYLE="text-align: right">36</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="4" STYLE="text-align: center">ARTICLE V</TD></TR>
<TR>
    <TD STYLE="vertical-align: middle; text-align: center; white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="4" STYLE="text-align: center">Additional Agreements</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="4" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 5.1.</TD>
    <TD>&nbsp;</TD>
    <TD>Conduct of Business</TD>
    <TD STYLE="text-align: right">37</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 5.2.</TD>
    <TD>&nbsp;</TD>
    <TD>Commercially Reasonable Efforts</TD>
    <TD STYLE="text-align: right">39</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 5.3.</TD>
    <TD>&nbsp;</TD>
    <TD>Exclusivity</TD>
    <TD STYLE="text-align: right">39</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 5.4.</TD>
    <TD>&nbsp;</TD>
    <TD>Access and Information; Advice of Changes</TD>
    <TD STYLE="text-align: right">39</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 5.5.</TD>
    <TD>&nbsp;</TD>
    <TD>Confidentiality</TD>
    <TD STYLE="text-align: right">40</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 5.6.</TD>
    <TD>&nbsp;</TD>
    <TD>Non-Competition; Right of First Negotiation</TD>
    <TD STYLE="text-align: right">41</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 5.7.</TD>
    <TD>&nbsp;</TD>
    <TD>Other Agreements</TD>
    <TD STYLE="text-align: right">45</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 5.8.</TD>
    <TD>&nbsp;</TD>
    <TD>Certain Tax Matters</TD>
    <TD STYLE="text-align: right">46</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 5.9.</TD>
    <TD>&nbsp;</TD>
    <TD>Public Announcements</TD>
    <TD STYLE="text-align: right">47</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 5.10.</TD>
    <TD>&nbsp;</TD>
    <TD>Employee Matters</TD>
    <TD STYLE="text-align: right">48</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 5.11.</TD>
    <TD>&nbsp;</TD>
    <TD>Regulatory Matters</TD>
    <TD STYLE="text-align: right">50</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 5.12.</TD>
    <TD>&nbsp;</TD>
    <TD>Trade Secrets; Patents; Trademarks</TD>
    <TD STYLE="text-align: right">51</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 5.13.</TD>
    <TD>&nbsp;</TD>
    <TD>Expenses</TD>
    <TD STYLE="text-align: right">51</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 5.14.</TD>
    <TD>&nbsp;</TD>
    <TD>Further Assurances</TD>
    <TD STYLE="text-align: right">51</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 5.15.</TD>
    <TD>&nbsp;</TD>
    <TD>Access</TD>
    <TD STYLE="text-align: right">52</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="4" STYLE="text-align: center">ARTICLE VI</TD></TR>
<TR>
    <TD STYLE="vertical-align: middle; text-align: center; white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="4" STYLE="text-align: center">Conditions Precedent</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="4" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 6.1.</TD>
    <TD>&nbsp;</TD>
    <TD>Conditions to Each Party&rsquo;s Obligations</TD>
    <TD STYLE="text-align: right">52</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 6.2.</TD>
    <TD>&nbsp;</TD>
    <TD>Conditions to Obligations of Buyer</TD>
    <TD STYLE="text-align: right">52</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 6.3.</TD>
    <TD>&nbsp;</TD>
    <TD>Conditions to Obligations of Seller</TD>
    <TD STYLE="text-align: right">53</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 6.4.</TD>
    <TD>&nbsp;</TD>
    <TD>Frustration of Closing Conditions</TD>
    <TD STYLE="text-align: right">53</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<TABLE BORDER="0" CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="4" STYLE="text-align: center">ARTICLE VII</TD></TR>
<TR>
    <TD STYLE="vertical-align: middle; text-align: center; width: 12%; white-space: nowrap">&nbsp;</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 81%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 5%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="4" STYLE="text-align: center">Indemnification</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="4" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 7.1.</TD>
    <TD>&nbsp;</TD>
    <TD>Indemnification of Buyer</TD>
    <TD STYLE="text-align: right">54</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 7.2.</TD>
    <TD>&nbsp;</TD>
    <TD>Indemnification of Seller Indemnified Parties</TD>
    <TD STYLE="text-align: right">54</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 7.3.</TD>
    <TD>&nbsp;</TD>
    <TD>Limitations</TD>
    <TD STYLE="text-align: right">55</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 7.4.</TD>
    <TD>&nbsp;</TD>
    <TD>Indemnification Claims</TD>
    <TD STYLE="text-align: right">55</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 7.5.</TD>
    <TD>&nbsp;</TD>
    <TD>Termination of Indemnification</TD>
    <TD STYLE="text-align: right">57</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 7.6.</TD>
    <TD>&nbsp;</TD>
    <TD>Exclusive Remedies</TD>
    <TD STYLE="text-align: right">57</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="4" STYLE="text-align: center">ARTICLE VIII</TD></TR>
<TR>
    <TD STYLE="vertical-align: middle; text-align: center; white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="4" STYLE="text-align: center">Termination</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="4" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 8.1.</TD>
    <TD>&nbsp;</TD>
    <TD>Termination</TD>
    <TD STYLE="text-align: right">57</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 8.2.</TD>
    <TD>&nbsp;</TD>
    <TD>Notice of Termination</TD>
    <TD STYLE="text-align: right">58</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 8.3.</TD>
    <TD>&nbsp;</TD>
    <TD>Effect of Termination</TD>
    <TD STYLE="text-align: right">58</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="4" STYLE="text-align: center">ARTICLE IX</TD></TR>
<TR>
    <TD STYLE="vertical-align: middle; text-align: center; white-space: nowrap">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="4" STYLE="text-align: center">General Provisions</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="4" STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 9.1.</TD>
    <TD>&nbsp;</TD>
    <TD>Rules of Construction</TD>
    <TD STYLE="text-align: right">58</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 9.2.</TD>
    <TD>&nbsp;</TD>
    <TD>Notices</TD>
    <TD STYLE="text-align: right">59</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 9.3.</TD>
    <TD>&nbsp;</TD>
    <TD>Consents and Approvals</TD>
    <TD STYLE="text-align: right">60</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 9.4.</TD>
    <TD>&nbsp;</TD>
    <TD>Counterparts</TD>
    <TD STYLE="text-align: right">60</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 9.5.</TD>
    <TD>&nbsp;</TD>
    <TD>Entire Agreement; No Third-Party Beneficiaries</TD>
    <TD STYLE="text-align: right">60</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 9.6.</TD>
    <TD>&nbsp;</TD>
    <TD>Assignment</TD>
    <TD STYLE="text-align: right">60</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 9.7.</TD>
    <TD>&nbsp;</TD>
    <TD>GOVERNING LAW</TD>
    <TD STYLE="text-align: right">60</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 9.8.</TD>
    <TD>&nbsp;</TD>
    <TD>Enforcement</TD>
    <TD STYLE="text-align: right">60</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 9.9.</TD>
    <TD>&nbsp;</TD>
    <TD>Severability</TD>
    <TD STYLE="text-align: right">61</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Section 9.10.</TD>
    <TD>&nbsp;</TD>
    <TD>Amendment; Waiver</TD>
    <TD STYLE="text-align: right">61</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Schedules</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 15%; white-space: nowrap">Schedule 1.1(a)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 83%; text-align: left">Business Employees</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Schedule 1.1(b)</TD><TD>&nbsp;</TD>
    <TD>Compound</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Schedule 1.1(c)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Dermatological Indications</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Schedule 1.1(d)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Seller Patents and Trademarks</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Schedule 2.1(b)(i)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Seller Wire Information</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Schedule 2.2(a)(v)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Assumed Contracts</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Schedule 2.2(a)(vi)</TD><TD>&nbsp;</TD>
    <TD>Permits</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Schedule 3.4(a)</TD><TD>&nbsp;</TD>
    <TD>Liens</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Schedule 3.4(b)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Good Title; Sufficiency of Assets</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Schedule 3.5(c)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Intellectual Property Rights</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Schedule 3.5(f)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Intellectual Property Licenses</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Schedule 3.5(i)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Existing Antibodies</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Schedule 3.6(a)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Excluded Contracts</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Schedule 3.7(b)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Material Permits</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Schedule 3.9(g)</TD><TD>&nbsp;</TD>
    <TD>Taxes</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Schedule 3.10(a)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Business Employee Benefit Plans</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Schedule 3.10(h)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Business Employee Information</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Schedule 3.11(a)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Regulatory Authorizations</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Schedule 3.11(b)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Clinical Trials</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Schedule 3.11(c)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Clinical Trial Budget</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Schedule 3.12</TD><TD>&nbsp;</TD>
    <TD>Inventory</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Schedule 3.17</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Related Party Transactions</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Schedule 5.1</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Interim Operating Covenants</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Schedule 5.6(b)(i)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Excluded Candidates</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Schedule 5.10(g)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Treatment of Seller Long-Term Incentive Awards</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">Schedule 5.12(d)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Specified Patents</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <B>Exhibits</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 15%; text-indent: -0.5in; padding-left: 0.5in; white-space: nowrap">Exhibit 2.4(b)(i)</TD><TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 83%; text-align: left">Form of Bill of Sale, Assignment and Assumption Agreement</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.5in; padding-left: 0.5in; white-space: nowrap">Exhibit 2.4(b)(ii)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Form of Escrow Agreement</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.5in; padding-left: 0.5in; white-space: nowrap">Exhibit 2.4(b)(iii)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Form of Patent Assignment Agreement</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.5in; padding-left: 0.5in; white-space: nowrap">Exhibit 2.4(b)(iv)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Form of Clinical Manufacturing Agreement</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.5in; padding-left: 0.5in; white-space: nowrap">Exhibit 2.4(b)(v)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Form of License to Occupy</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.5in; padding-left: 0.5in; white-space: nowrap">Exhibit 2.4(b)(vi)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Form of Transition Services Agreement</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.5in; padding-left: 0.5in; white-space: nowrap">Exhibit 2.4(b)(vii)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Form of IP License Agreement</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt 0.7pt 0pt 0; text-align: center"><FONT STYLE="font-variant: normal"></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt 0.7pt 0pt 0; text-align: center"><FONT STYLE="font-variant: normal"><B>ASSET
PURCHASE AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">This Asset Purchase Agreement
(this &ldquo;<U>Agreement</U>&rdquo;) dated as of December 7, 2019 is entered into between Janssen Biotech, Inc., a Pennsylvania
corporation (&ldquo;<U>Buyer</U>&rdquo;), and XBiotech Inc., a corporation existing under the laws of the Province of British Columbia
(&ldquo;<U>Seller</U>&rdquo;). Buyer and Seller are sometimes individually referred to herein as a &ldquo;<U>Party</U>&rdquo; and
are sometimes collectively referred to herein as the &ldquo;<U>Parties</U>&rdquo;. Certain capitalized terms used herein have the
meanings ascribed to them in <U>Section&nbsp;1.1</U>.</P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt 1in; text-align: center">&nbsp;</P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin: 0pt 1in; text-align: center"><B>RECITALS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">WHEREAS, Seller desires
to sell all of Seller&rsquo;s and its Affiliates&rsquo; right, title and interest in, to and under the Purchased Assets and transfer
the Assumed Liabilities to Buyer, and Buyer wishes to purchase from Seller all of Seller&rsquo;s and its Affiliates&rsquo; right,
title and interest in, to and under the Purchased Assets and to assume the Assumed Liabilities, upon the terms and subject to the
conditions set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">NOW, THEREFORE, in consideration
of the mutual benefits to be derived from this Agreement, and of the representations, warranties, conditions, agreements and promises
contained herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the
Parties, intending to be legally bound, hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><B>ARTICLE
I<BR>
<BR>
Definitions; Interpretation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 1.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Definitions</U>. For purposes of this Agreement, the following terms shall have the corresponding meanings set forth
below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Accounts Payable</U>&rdquo;
means all trade accounts payable, regardless of when asserted, billed or imposed, of Seller or its Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Act</U>&rdquo;
means the United States Federal Food, Drug, and Cosmetic Act, as amended, and the rules, regulations, requirements, written advisory
comments and any formal guidance promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Action</U>&rdquo;
means any claim, action, suit, arbitration, inquiry, audit, proceeding or investigation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Affiliate</U>&rdquo;
of any Person means another Person that directly or indirectly, through one or more intermediaries, Controls, is Controlled by
or is under common Control with, such first Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Agreement</U>&rdquo;
has the meaning set forth in the preamble hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Assumed Contracts</U>&rdquo;
has the meaning set forth in <U>Section&nbsp;2.2(a)(vi)</U>.</P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Assumed Liabilities</U>&rdquo;
means (i) the Liabilities under the Assumed Contracts accruing with respect to the period commencing after the later of the Closing
and the applicable Transfer Date (but, for the avoidance of doubt, excluding any Liability arising from or relating to the performance
or non-performance thereof on or prior to the later of the Closing and the applicable Transfer Date), (ii) any Assumed Taxes, (iii)
any Liabilities arising out of, relating to or resulting from the employment or termination of employment of any Transferred Business
Employee after the applicable Transfer Time, (iv) any Liabilities arising out of, relating to or resulting from clinical trials
for atopic dermatitis or hidradenitis suppurativa indications accruing on or after the Closing Date and (v) all other Liabilities
arising out of, relating to or resulting from Buyer&rsquo;s ownership or operation of the Business on or after the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Assumed Taxes</U>&rdquo;
means any Taxes arising out of, or with respect to, the Purchased Assets for any Post-Closing Tax Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Bill of Sale,
Assignment and Assumption Agreement</U>&rdquo; has the meaning set forth in <U>Section&nbsp;2.4(b)(i)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Biological
Materials</U>&rdquo; means (i) any tissues, cells, cell lines, organisms, blood samples, genetic material, antibodies and other
biological substances and materials (including an aliquot of the plasmid DNA used at cell line transfection) and any Research Tools
and (ii) any biological products, as such term is defined in Section 351 of the PHS Act, in each case that are owned or otherwise
Controlled by Seller or any of its Affiliates on the Closing Date and that are primarily related to the Business or otherwise reasonably
necessary to conduct the Business as conducted during the Reference Period. For the avoidance of doubt, references to &ldquo;Biological
Materials&rdquo; shall be deemed to include all materials of the type referred to in clause (i) or (ii) above that are reasonably
necessary to conduct the Business that are not readily available from commercial sources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Books and Records</U>&rdquo;
means all books, records, files, documents and Tax Returns to the extent related to the Compound or any Product or the Exploitation
thereof, any other Purchased Assets, or the Compound Program (including Regulatory Documentation, research and development records
(including reports detailing the history of the applicable host CHO cell line, creation of the plasmid DNA construct, generation
of the manufacturing cell line, measures taken to assure monoclonality, MCB/WCB testing and results, any genetic characterization
studies performed and the full nucleotide sequence of applicable plasmid DNA (gb file)), correspondence and, to the extent not
originals, copies of all files relating to the filing, prosecution, issuance, maintenance, enforcement or defense of any Intellectual
Property Rights, including any written correspondence with any Third Party, records and documents related to research and pre-clinical
and clinical testing and studies relating to the Compound or any Product or the Exploitation thereof conducted by or on behalf
of Seller or any of its Affiliates or the Compound Program, including any laboratory and engineering notebooks and manufacturing
records, procedures, tests, dosage, criteria for patient selection, study protocols and investigators&rsquo; brochures) in all
forms in which they are stored or maintained (whether electronic or otherwise), and all data (including Data) and information included
or referenced in any of the foregoing, in each case that are owned or otherwise Controlled by or in the possession of Seller or
any of its Affiliates.</P>

<!-- Field: Page; Sequence: 7; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Business</U>&rdquo;
means the Compound Program and the Purchased Assets, including the Compound and all Products and the potential Exploitation thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Business Day</U>&rdquo;
means any day other than (a) a Saturday or Sunday or (b) a day on which banking institutions located in New York City are permitted
or required by applicable Law to remain closed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Business Employee</U>&rdquo;
means each employee of Seller and its Affiliates who is set forth on <U>Schedule 1.1(a)</U>, which <U>Schedule 1.1(a)</U> shall
be updated by Seller prior to the Closing to reflect any employment terminations or other changes in status; <U>provided</U> that,
if (a) the employment of any individual listed on <U>Schedule 1.1(a)</U> is terminated prior to the Closing Date, (b) any such
individual rejects an offer of employment pursuant to <U>Section 5.10</U> or (c) any such individual is no longer an active employee
as of the Closing Date, then if Buyer so elects, Seller and Buyer shall reasonably cooperate to mutually agree on another employee
of Seller and its Affiliates who is sufficiently knowledgeable regarding the Compound Program, including the Compound and all Products
and the potential Exploitation thereof, to replace such individual, and <U>Schedule 1.1(a)</U> and <U>Schedule 3.10(h)</U> shall
be updated to include such employee; and <U>provided</U> further that <U>Schedule 1.1(a)</U> shall be comprised of no more than
ten Business Employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Business Employee
Benefit Plan</U>&rdquo; means any (a) &ldquo;employee benefit plan&rdquo; as defined in Section 3(3) of ERISA, whether or not subject
to ERISA, or (b) employment agreement, offer letter, severance arrangement, change in control arrangement, retention agreement
or plan, deferred compensation arrangement, sales commission plan or program or other compensatory or benefit plan, agreement,
program, policy or arrangement, in each case that is sponsored, maintained or contributed to by Seller or any of its Affiliates
for the benefit of a Business Employee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Buyer</U>&rdquo;
has the meaning set forth in the preamble hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Buyer Indemnified
Party</U>&rdquo; has the meaning set forth in <U>Section&nbsp;7.1(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Cap</U>&rdquo;
has the meaning set forth in <U>Section&nbsp;7.3(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Clinical Manufacturing
Agreement</U>&rdquo; has the meaning set forth in <U>Section 2.4(b)(v)</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Closing</U>&rdquo;
has the meaning set forth in <U>Section 2.4(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Closing Date</U>&rdquo;
has the meaning set forth in <U>Section 2.4(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Code</U>&rdquo;
means the Internal Revenue Code of 1986, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Compound</U>&rdquo;
means the monoclonal antibody known as bermekimab (MABp1), the sequence of which is set forth in <U>Schedule 1.1(b)</U>.</P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Compound Program</U>&rdquo;
means the program of research and development carried out on or prior to the Closing Date utilizing the Compound in research and/or
discovery efforts or the Exploitation of the Compound.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Confidentiality
Agreement</U>&rdquo; means the letter agreement, dated as of January 5, 2019, between Janssen Research &amp; Development, LLC and
Seller.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Contemplated
Transactions</U>&rdquo; means the transactions contemplated by this Agreement and any Related Document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Contracts</U>&rdquo;
means any loan or credit agreement, bond, debenture, note, mortgage, indenture, lease, supply agreement, license agreement, development
agreement, distribution agreement, contract research organization agreement or other legally binding contract, agreement, obligation,
commitment, arrangement, understanding or instrument, whether oral or written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Control</U>&rdquo;
including its various tenses and derivatives (such as &ldquo;<U>Controlled</U>&rdquo; and &ldquo;<U>Controlling</U>&rdquo;) means
(a) when used with respect to any Person, the possession, directly or indirectly, of the power to direct or cause the direction
of the management and policies of such entity, whether through the ownership of voting securities, by Contract or otherwise, (b)
when used with respect to any security, the possession, directly or indirectly, of the power to vote, or to direct the voting of,
such security or the power to dispose of, or to direct the disposition of, such security and (c) when used with respect to any
Intellectual Property Rights, possession of the right, whether directly or indirectly, and whether by ownership, license or otherwise,
to assign or grant a license, sublicense or other right to or under such Intellectual Property Rights or to compel another to do
so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Data</U>&rdquo;
means all databases and data, including all compilations thereof, and all rights therein, owned or Controlled by Seller or any
of its Affiliates that (i) were collected, compiled, generated or used in connection with the Compound Program on or prior to the
Closing Date or (ii) otherwise are related to the Compound or any Product or the Exploitation thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Data Room</U>&rdquo;
has the meaning set forth in <U>Section&nbsp;1.2</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Dermatology</U>&rdquo;
means the treatment of any disorder (i) set forth on <U>Schedule 1.1(c)</U>, (ii) reviewed by or under the jurisdiction of the
FDA&rsquo;s Division of Dermatology and Dental Products as of the date hereof or (iii) that is not reviewed by or under the jurisdiction
of any division of the FDA as of the date hereof, but that subsequently becomes reviewed by or under the jurisdiction of the FDA&rsquo;s
Division of Dermatology and Dental Products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Dollars</U>&rdquo;
or &ldquo;<U>$</U>&rdquo; means United States dollars.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&ldquo;<U>ERISA</U>&rdquo; means the Employee
Retirement Income Security Act of 1974, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>ERISA Affiliate</U>&rdquo;
means, with respect to any entity, trade or business, any other entity, trade or business that is, or was at the relevant time,
a member of a group described in
</P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Section 414(b), (c),
(m) or (o) of the Code or Section 4001(b)(1) of ERISA that includes or included the first entity, trade or business, or that is,
or was at the relevant time, a member of the same &ldquo;controlled group&rdquo; as the first entity, trade or business pursuant
to Section 4001(a)(14) of ERISA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Escrow Agent</U>&rdquo;
has the meaning set forth in <U>Section&nbsp;2.7(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Escrow Agreement</U>&rdquo;
has the meaning set forth in <U>Section&nbsp;2.4(b)(ii)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Escrow Amount</U>&rdquo;
has the meaning set forth in <U>Section&nbsp;2.1(b)(i)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Escrow Consideration</U>&rdquo;
has the meaning set forth in <U>Section&nbsp;2.7(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Escrow Fund</U>&rdquo;
has the meaning set forth in <U>Section&nbsp;2.7(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Escrow Termination
Date</U>&rdquo; has the meaning set forth in <U>Section&nbsp;2.7(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<B>[*****]</B>
<U>Countries</U>&rdquo; means the <B>[*****] </B>and <B>[*****]</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Excluded Assets</U>&rdquo;
has the meaning set forth in <U>Section 2.2(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Excluded Contracts</U>&rdquo;
shall mean the Contracts set forth on <U>Schedule 3.6(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Excluded Liabilities</U>&rdquo;
has the meaning set forth in <U>Section 2.3(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Excluded Taxes</U>&rdquo;
means (i) any Taxes arising out of, or with respect to, the Purchased Assets for any Pre-Closing Tax Period, (ii) any Taxes of
Seller or any of its Affiliates for any taxable period and (iii) any Transfer Taxes that are allocated to Seller pursuant to <U>Section
5.8(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Existing Antibody</U>&rdquo;
has the meaning set forth in <U>Section 3.5(i)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Exploit</U>&rdquo;
means to make, have made, import, use, sell, offer for sale, or otherwise dispose of, including to research, develop, register,
modify, enhance, improve, manufacture, have manufactured, store, formulate, optimize, export, transport, distribute, commercialize,
promote, market, have sold or otherwise dispose of. &ldquo;<U>Exploiting</U>&rdquo;, &ldquo;<U>Exploitation</U>&rdquo; and other
forms of the word &ldquo;Exploit&rdquo; shall have correlative meanings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>FCPA</U>&rdquo;
has the meaning set forth in <U>Section 3.18(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>FDA</U>&rdquo;
has the meaning set forth in <U>Section&nbsp;3.11(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>GAAP</U>&rdquo;
means the United States generally accepted accounting principles in effect from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">[*****] Text omitted for confidential treatment.
The redacted information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly
disclosed.</P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Governmental
Authority</U>&rdquo; means any Federal, state, local or foreign government, any court, tribunal, administrative, regulatory or
other governmental agency, department, commission or authority or any non-governmental self-regulatory agency, commission or authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>IND</U>&rdquo;
means (i) any investigational new drug application relating to a Product filed with the FDA pursuant to 21 C.F.R. Part 312, or
any comparable filing made with a Governmental Authority in another country (including the submission to a competent authority
of a request for an authorization concerning a clinical trial, as envisaged in <U>Article 9</U>, paragraph 2, of European Directive
2001/20/EC, or any other exemption legitimizing the use of the Product in a clinical investigation), and (ii) all supplements and
amendments that may be filed with respect to the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Indemnified
Party</U>&rdquo; has the meaning set forth in <U>Section&nbsp;7.4(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Indemnifying
Party</U>&rdquo; has the meaning set forth in <U>Section&nbsp;7.4(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Indemnity Threshold</U>&rdquo;
has the meaning set forth in <U>Section 7.3(a)(i)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Intellectual
Property Rights</U>&rdquo; means any (a) patents, patent applications, (including in each case any continuation, continuation-in-part,
division, renewal, patent term, extension (including any supplemental protection certificate), reexamination or reissue thereof)
(collectively, &ldquo;<U>Patents</U>&rdquo;); (b) registered and unregistered trademarks, trade dress, trade names, logos, design
rights, service marks, together with the goodwill pertaining to the foregoing, and all applications, registrations and renewals
therefor (collectively, &ldquo;<U>Trademarks</U>&rdquo;); (c) registered and unregistered copyrights, works of authorship, copyrightable
works (published or unpublished) and all applications, registrations and renewals therefor (collectively, &ldquo;<U>Copyrights</U>&rdquo;);
(d) domain names; (e) software, computer programs and applications (whether in source code, object code or other form) algorithms,
databases, documentation and technology supporting the foregoing (excluding off the shelf software) (collectively, &ldquo;<U>Software</U>&rdquo;);
and (f) trade secrets (&ldquo;<U>Trade Secrets</U>&rdquo;), know-how (including all ideas, concepts, research and development,
composition information and embodiments, manufacturing and production processes, techniques and information, specifications, technical
and business data, Data, designs, drawings, suppliers lists, pricing and cost information, and data and know-how embodied in business
and marketing plans and proposals), other proprietary information and other proprietary intellectual property rights, and all copies
and tangible embodiments of the foregoing in whatever form or medium.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Inventory</U>&rdquo;
means, with respect to or to the extent used in the Compound or any Product, all inventory of active pharmaceutical ingredient,
intermediates, specific raw materials, components and consumables and finished product forms, together with all work-in-progress,
packaging materials and any materials that were subject to testing and required preservation, owned by Seller or any of its Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&ldquo;<U>IP License Agreement</U>&rdquo;
has the meaning set forth in <U>Section 2.4(b)(ix)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&ldquo;<U>IRS</U>&rdquo; means the United
States Internal Revenue Service.</P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Law</U>&rdquo;
means any federal, state, local or foreign constitution, treaty, law, statute, ordinance, rule or regulation (including any written
advisory comments or formal interpretation, guidance, directive or policy thereunder), order, writ, award, decree, injunction,
judgment, stay or restraining order of any Governmental Authority, the terms of any permit, and any other ruling or decision of,
agreement with or by, or any other requirement of, any Governmental Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Liabilities</U>&rdquo;
means any liabilities, obligations and commitments, whether accrued or fixed, absolute or contingent, known or unknown, determined
or determinable, due or to become due, or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>License to
Occupy</U>&rdquo; has the meaning set forth in <U>Section 2.4(b)(vi)</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Lien</U>&rdquo;
means any lien (statutory or otherwise), security interest, pledge, hypothecation, mortgage, assessment, lease, claim, levy, license,
defect in title, charge, or any other Third Party right, license or property interest of any kind, or any conditional sale or other
title retention agreement, right of first option, right of first refusal or similar restriction, any covenant not to sue, or any
restriction on use, transfer, receipt of income or exercise of any other attribute of ownership or any agreement to give any of
the foregoing in the future or similar encumbrance of any kind or nature whatsoever.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Losses</U>&rdquo;
has the meaning set forth in <U>Section&nbsp;7.1(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>MAA</U>&rdquo;
means a New Drug Application or Biologics License Application, each as defined in the Act, and any corresponding foreign application,
registration or certification, necessary to commercialize and market, or primarily related to the commercialization and marketing
of, a Product in a particular country or group of countries, but not including pricing and reimbursement approvals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Material Adverse
Effect</U>&rdquo; means any change, effect, event, occurrence, state of facts or development which individually or in the aggregate
would reasonably be expected to result in, or has resulted in, any change or effect, that&nbsp;(a) is materially adverse to the
Business; (b)&nbsp;would reasonably be expected to prevent or materially impede, materially interfere with, materially hinder or
materially delay the consummation of the Contemplated Transactions or (c) would reasonably be expected to create or impose a material
limitation on the ability of Buyer to acquire valid and marketable title to the Purchased Assets free and clear of all Liens or
to freely Exploit the Purchased Assets; <U>provided</U> that, for purposes of clause (a), none of the following shall be deemed,
either alone or in combination, to constitute, and none of the following shall be taken into account in determining whether there
has been or will be, a Material Adverse Effect: (i)&nbsp;any change, effect, event, occurrence, state of facts or development relating
to the economy in general in the United States or in any other jurisdiction in which the Seller has operations or conducts business,
including any changes in financial, banking or securities markets in general, any disruption thereof and any decline in the price
of any security or any market index or any change in prevailing interest rates, so long as the effects do not disproportionately
impact the Business, (ii) any change, effect, event, occurrence, state of facts or development reasonably attributable to conditions
affecting the pharmaceutical industry, so long as the effects do not disproportionately impact the Business, (iii) the public announcement
of this Agreement and the Contemplated Transactions, (iv)&nbsp;earthquakes, hurricanes, tornadoes, natural disasters or global,
national or regional political conditions, including hostilities, military actions, political instability, acts of terrorism or
war or any escalation or material worsening of any such hostilities, military actions, political instability, acts of terrorism
or war existing or underway as of the date hereof (other than any of the foregoing that causes any material damage or destruction
to or renders unusable any material Purchased Assets and so long as the effects do not disproportionately impact the Business),
(v) any effect that results from any action taken at the express prior written request of Buyer or with Buyer&rsquo;s prior written
consent or (vi) changes in Law or GAAP or any interpretation thereof, so long as the effects do not disproportionately impact the
Business.</P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Milestone Payment</U>&rdquo;
has the meaning set forth in <U>Section 2.5(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Negotiation
Notice</U>&rdquo; has the meaning set forth in <U>Section 5.6(c)(iii)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Negotiation
Period</U>&rdquo; has the meaning set forth in <U>Section 5.6(c)(iii)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>New Antibody</U>&rdquo;
has the meaning set forth in <U>Section 5.6(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>New Antibody
Product</U>&rdquo; has the meaning set forth in <U>Section 5.6(c)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Non-Assignable
Right</U>&rdquo; has the meaning set forth in <U>Section&nbsp;2.6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Non-Dermatological
Indication</U>&rdquo; means any disorder that is not included in clauses (i), (ii) or (iii) of the definition of Dermatology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Offer Notice</U>&rdquo;
has the meaning set forth in <U>Section 5.6(c)(i)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Offer Period</U>&rdquo;
has the meaning set forth in <U>Section 5.6(c)(ii)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Order</U>&rdquo;
means any writ, judgment, decree, injunction or similar order, including consent orders, of any Governmental Authority (in each
such case whether preliminary or final).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Outstanding
Claim Reserve</U>&rdquo; has the meaning set forth in <U>Section&nbsp;2.7(c)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&ldquo;<U>Parent</U>&rdquo; has the meaning
set forth in <U>Section 5.10(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Party</U>&rdquo;
or &ldquo;<U>Parties</U>&rdquo; has the meaning set forth in the preamble hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Patent Assignment
Agreement</U>&rdquo; has the meaning set forth in <U>Section&nbsp;2.4(b)(iii)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Permits</U>&rdquo;
means all approvals, authorizations, certificates, filings, franchises, licenses, notices, clearances and permits of or with all
Governmental Authorities, including all applications for any of the foregoing, together with any renewals, extensions or modifications
thereof and additions thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Permitted Liens</U>&rdquo;
means, collectively, (i) statutory liens for Taxes, assessments and governmental charges not yet due and payable or that are being
contested in good faith by appropriate proceedings and for which appropriate reserves have been maintained in accordance with GAAP,
(ii) statutory Liens of landlords and Liens of carriers, warehousemen, mechanics, material men and other Liens imposed by law arising
or incurred in the ordinary course of business for amounts that are not yet due and payable and, if required under GAAP, for which
appropriate reserves have been created or that are being contested in good faith by appropriate proceedings and that are not resulting
from any breach, violation or default by Seller or any of its Affiliates of any Contract or applicable Law and (iii) other imperfections
of title or Liens, if any, that, individually or in the aggregate, are not material to the Business or the Purchased Assets.</P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Person</U>&rdquo;
means an individual, corporation, partnership, limited liability company, joint venture, association, trust, unincorporated organization
or other entity or any Governmental Authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>PHS Act</U>&rdquo;
means the means the United States Public Health Service Act, as amended, and the rules, regulations, requirements, written advisory
comments and formal guidance promulgated thereunder, as may be in effect from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&ldquo;<U>Post-Closing Tax Period</U>&rdquo;
means any Tax period (or portion thereof) beginning after the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&ldquo;<U>Pre-Closing Tax Period</U>&rdquo;
means any Tax period (or portion thereof) ending on or before the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Product</U>&rdquo;
means any pharmaceutical product containing the Compound, including all dosage forms, presentations, formulations and line extensions
thereof, including a pharmaceutical product which is comprised of the Compound and other pharmaceutically active compound(s) and/or
ingredients, any prototypes thereof and any variations thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Public Official</U>&rdquo;
has the meaning set forth in <U>Section 3.18(c)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Purchase Price</U>&rdquo;
means an amount equal to $750,000,000.00.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Purchased Assets</U>&rdquo;
has the meaning set forth in <U>Section&nbsp;2.2(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Quality Assurance
Agreement</U>&rdquo; has the meaning set forth in <U>Section 5.16(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Reference Period</U>&rdquo;
means the 18 month period ending on and including the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Regulatory
Application</U>&rdquo; means an application submitted to a Governmental Authority that issues Regulatory Authorizations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Regulatory
Authorizations</U>&rdquo; means, with respect to any jurisdiction, any and all approvals (including pricing and reimbursement approvals),
licenses, clearances, registrations or authorizations of any Governmental Authority necessary for or primarily related to the investigation,
development, manufacture, sale or marketing of any pharmaceutical compound or (bio)pharmaceutical product in such jurisdiction,
including, where applicable, (i) INDs, MAAs and supplements and amendments thereto, (ii) pre- and post-approval marketing authorizations
(including any prerequisite manufacturing approval or authorization related thereto) and (iii) labeling approval.</P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Regulatory
Documentation</U>&rdquo; means any and all (i) applications, registrations, licenses, authorizations and approvals (including all
Regulatory Authorizations), and non-clinical and clinical study authorization applications or notifications (including all supporting
files, writings, data, studies and reports) submitted to a Governmental Authority or institutional review board or research ethics
committee, as applicable, with a view to the obtaining or maintaining of any Regulatory Authorization, including any Investigational
Medicinal Product Dossier (IMPD), (ii) correspondence to or with the FDA, EMA or any other Governmental Authority (including minutes
and official contact reports relating to any communications with any Governmental Authority), (iii) pharmacovigilance databases,
adverse event reports and associated documents, investigations of adverse event reports, and any other records related to safety
reporting, (iv) manufacturing records and (v) nonclinical, clinical and other data contained or referenced in or supporting any
of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Related Documents</U>&rdquo;
means, other than this Agreement, all agreements, certificates and documents signed and delivered by either Party in connection
with this Agreement or the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Representatives</U>&rdquo;
means, with respect to any Person, such Person&rsquo;s directors, officers, managers, employees, counsel, consultants, accountants,
financial advisors, lenders and other agents and representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Required Commercialization
Authorizations</U>&rdquo; means, with respect to any product, indication and country, all Regulatory Authorizations necessary to
market and sell such product for such indication in such country (including all approvals or determinations by a Governmental Authority
for the pricing or pricing reimbursement for such product, even if not legally required to sell such product in such country),
as determined by Buyer in its reasonable discretion; <U>provided</U>, the term &ldquo;sell&rdquo; as used in this definition shall
not include sales to Affiliates or sales associated with treatment IND, expanded use, compassionate use, early access or named
patient programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Research Tools</U>&rdquo;
means cDNAs, antibodies, cell lines, knock-out animals, assays and other similar research tools.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Restricted
Actions</U>&rdquo; has the meaning set forth in <U>Section 5.6(c)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Restricted
Period</U>&rdquo; has the meaning set forth in <U>Section 5.6(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Seller</U>&rdquo;
has the meaning set forth in the preamble hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Seller Indemnified
Party</U>&rdquo; has the meaning set forth in <U>Section&nbsp;7.2(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Seller Intellectual
Property</U>&rdquo; means (i) all Patents and Trademarks owned or Controlled by Seller or any of its Affiliates on the Closing
Date that are set forth on <U>Schedule 1.1(d)</U> and (ii) all Trade Secrets and know-how owned or Controlled by Seller or any
of its Affiliates on the Closing Date that are used exclusively in connection with the Business and, in each of cases (i) and (ii),
the right to recover for past infringement of any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Seller Regulatory
Authorizations</U>&rdquo; means any and all (i) Regulatory Authorizations and (ii) Regulatory Applications, in either case that
are (a) owned or otherwise Controlled by Seller or any of its Affiliates on the Closing Date and (b) used primarily in connection
with the Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Seller Regulatory
Documentation</U>&rdquo; means any and all Regulatory Documentation, including all Seller Regulatory Authorizations, that is owned
by, or otherwise Controlled by or in the possession of, Seller or any of its Affiliates on the Closing Date and that (i) was acquired,
collected, compiled, generated or used in connection with Business prior to the Closing Date or (ii) is otherwise used primarily
in connection with the Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Seller&rsquo;s
Charter</U>&rdquo; has the meaning set forth in <U>Section&nbsp;3.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Seller&rsquo;s
Knowledge</U>&rdquo; (and similar phrases) means, with respect to any matter in question, (i) the actual knowledge of Seller&rsquo;s
following officers: John Simard, Norma I. Gonzalez, Queena Han and Sushma Shivaswamy, after making due inquiry of their direct
reports, and (ii) the actual knowledge of Stanley Kim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Social Security
Act</U>&rdquo; has the meaning set forth in <U>Section&nbsp;3.11(f)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Specified Indications</U>&rdquo;
shall mean (i) Dermatology indications and (ii) any other indications that are deemed to be Specified Indications pursuant to <U>Section
2.5(d)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Specified Representations</U>&rdquo;
has the meaning set forth in <U>Section&nbsp;7.3(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Subsidiary</U>&rdquo;
of any Person means another Person, an amount of the voting securities, other voting rights or voting partnership interests of
which is sufficient to elect at least a majority of its board of directors or other governing body (or, if there are no such voting
interests, 50% or more of the equity interests of which) is owned directly or indirectly by such first Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Tax</U>&rdquo;
or &ldquo;<U>Taxes</U>&rdquo; means (whether disputed or not) all (a) U.S., Canadian or other&nbsp;federal, state, provincial,
local and foreign income, property, sales, use, excise, withholding, payroll, employment, social security, capital gain, alternative
minimum, transfer and other taxes and similar governmental charges, in each case in the nature of a tax, including any interest,
penalties and additions with respect thereto, (b)&nbsp;liability for the payment of any amounts of the type described in clause&nbsp;(a)
as a result of being a member of an affiliated, consolidated, combined, unitary or aggregate group or as a transferee or successor
and (c)&nbsp;liability for the payment of any amounts as a result of being party to any tax sharing agreement or as a result of
any express or implied obligation to indemnify any other Person with respect to the payment of any amounts of the type described
in clause&nbsp;(a) or (b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Tax Return</U>&rdquo;
means all returns (including amended returns), requests for extensions of time, claims for refund, declarations of estimated Tax
payments, reports, estimates, information returns and statements, including any related or supporting information with respect
to any of the foregoing, filed or required to be filed with any Taxing Authority in connection with the determination, assessment,
collection or administration of any Taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Taxing Authority</U>&rdquo;
means any Governmental Authority or any quasi-governmental body exercising Tax regulatory authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Third Party</U>&rdquo;
means any Person other than: (a) Seller or Buyer or (b) any Affiliates of Seller or Buyer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Third Party
Claim</U>&rdquo; has the meaning set forth in <U>Section&nbsp;7.4(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Transfer Date</U>&rdquo;
has the meaning set forth in <U>Section 2.6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Transfer Taxes</U>&rdquo;
has the meaning set forth in <U>Section&nbsp;5.8(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&ldquo;<U>Transfer Time</U>&rdquo; means 10:00
a.m., New York City time, on the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&ldquo;<U>Transferred Business Employee</U>&rdquo;
has the meaning set forth in <U>Section 5.10(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Transition
Services Agreement</U>&rdquo; has the meaning set forth in <U>Section 2.4(b)(vii)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>XBiotech USA</U>&rdquo;
has the meaning set forth in <U>Section&nbsp;2.4(b)(i)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 1.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Interpretation</U>. When a reference is made in this Agreement to an Article, a Section, Exhibit or Schedule, such reference
shall be to an Article of, a Section of, or an Exhibit or Schedule to, this Agreement unless otherwise indicated. The table of
contents and headings contained in this Agreement, any Related Document or in any Exhibit or Schedule hereto are for reference
purposes only and shall not affect in any way the meaning or interpretation of this Agreement, such Related Document or such Exhibit
or Schedule. Whenever the words &ldquo;include&rdquo;, &ldquo;includes&rdquo; or &ldquo;including&rdquo; are used in this Agreement
or any Related Document, they shall be deemed to be followed by the words &ldquo;without limitation&rdquo;. The word &ldquo;or,&rdquo;
when used in this Agreement, has the inclusive meaning represented by the phrase &ldquo;and/or.&rdquo; The words &ldquo;hereof&rdquo;,
&ldquo;herein&rdquo; and &ldquo;hereunder&rdquo; and words of similar import when used in this Agreement shall refer to this Agreement
as a whole and not to any particular provision of this Agreement. References to the &ldquo;date hereof&rdquo; refer to the date
of this Agreement. &ldquo;Extent&rdquo; in the phrase &ldquo;to the extent&rdquo; means the degree to which a subject or other
thing extends, and such phrase does not mean simply &ldquo;if&rdquo;. For purposes of this Agreement and the Related Documents,
the phrases &ldquo;delivered or made available to Buyer prior to the date hereof&rdquo;, &ldquo;delivered or made available to
Buyer in the data room prior to the date hereof&rdquo;, &ldquo;has made available to Buyer prior to the date hereof&rdquo; or &ldquo;has
made available to Buyer in the data room prior to the date hereof&rdquo; and similar expressions in respect of any document or
information will be construed for all purposes of this Agreement and the Related Documents as meaning that a copy of such document
or information was filed and made available for viewing by Buyer in the electronic data rooms hosted by Intralinks (the &ldquo;<U>Data
Room</U>&rdquo;) in each case no later than two Business Days prior to the date hereof. All terms defined in this Agreement shall
have the defined meanings when used in any certificate or other document made or delivered pursuant hereto unless otherwise defined
therein. The definitions contained in this Agreement are applicable to the singular as well as the plural forms of such terms and
to the masculine as well as to the feminine and neuter genders of such term. Any Contract or statute defined or referred to herein
or in any Contract that is referred to herein means (a)&nbsp;in the case of any statute, such statute and any comparable statute
that from time to time replaces such statute by succession and (b)&nbsp;in the case of any Contract, such Contract and all amendments,
modifications and attachments thereto and instruments incorporated therein. References to a Person are also to its permitted successors
and assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><B>ARTICLE
II</B><BR>
<BR>
<B>Purchase and Sale</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 2.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Purchase and Sale of Purchased Assets; Purchase Price</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Pursuant to the terms and subject to the conditions of this Agreement, at the Closing, Seller shall, and shall cause each
of its Affiliates owning or otherwise Controlling any of the Purchased Assets to, sell, convey, deliver, transfer and assign to
Buyer (or its designated Affiliate), free and clear of all Liens, other than Permitted Liens, and Buyer (or its designated Affiliate)
shall purchase, take delivery of and acquire from Seller (and its Affiliates) all of Seller&rsquo;s (and its Affiliates&rsquo;)
right, title and interest in, to and under all of the Purchased Assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In consideration of the sale, conveyance, delivery, transfer and assignment of the Purchased Assets to Buyer (or its designated
Affiliate) and Seller&rsquo;s other covenants and obligations hereunder, upon the terms and subject to the conditions hereof:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>at the Closing, Buyer shall make the following payments: (1) to the Escrow Agent, by wire transfer of immediately available
funds to the account designated by the Escrow Agent in writing as set forth in the Escrow Agreement, $75,000,000 (the &ldquo;<U>Escrow
Amount</U>&rdquo;), and (2) to Seller (and/or to its designees), by wire transfer of immediately available funds to the account(s)
set forth on <U>Schedule&nbsp;2.1(b)(i)</U>, the Purchase Price <U>minus</U> the Escrow Amount;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>if and when payable pursuant to <U>Section&nbsp;2.5</U>, Buyer shall make the Milestone Payments to Seller in accordance
with <U>Section&nbsp;2.5</U>; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>at the Closing, Buyer shall assume the Assumed Liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 2.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Purchased Assets; Excluded Assets</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The term &ldquo;<U>Purchased Assets</U>&rdquo; means all of Seller&rsquo;s (and its Affiliates&rsquo;) right, title and
interest in, to and under the following properties and assets (tangible or intangible), other than the Excluded Assets:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>all Biological Materials;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>all Seller Regulatory Documentation, including, for the avoidance of doubt, original and, if available, electronic copies;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>all Seller Intellectual Property, including the registrations and applications set forth on <U>Schedule&nbsp;1.1(d)</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>all Books and Records, and all originals of any tangible embodiments of Seller Intellectual Property, including original
files of any Patents included in the Seller Intellectual Property; <U>provided</U>, <U>however</U>, that Seller may retain a copy
of any such Books and Records to the extent (A) necessary for Tax, regulatory compliance or accounting purposes, (B) necessary
to comply with its obligations under any Related Documents, including the Clinical Manufacturing Agreement, but solely for the
period required for such compliance, (C) such Books and Records relate to the Exploitation of any product that does not contain
or comprise, and would not reasonably be expected to compete, directly or indirectly, with, a Compound, so long as redactions are
made to exclude all Seller Intellectual Property and other information relating to the Compound or any Product or (D) such Books
and Records do not primarily relate to the Business, so long as redactions are made to exclude all Seller Intellectual Property
and other information relating to the Compound or any Product;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the Contracts set forth on <U>Schedule 2.2(a)(v)</U> (including all agreements relating to clinical trials for the atopic
dermatitis and hidradenitis suppurativa indications, collectively, the &ldquo;<U>Assumed Contracts</U>&rdquo;), including all rights
thereunder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>all Permits necessary for or primarily related to the Business, including as set forth on <U>Schedule 2.2(a)(vi)</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(vii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>all Actions, rights of recovery, and rights of indemnification or setoff against Third Parties and other claims arising
out of or relating to the Business or the Assumed Liabilities that relate to the Business or the Assumed Liabilities, in each case
subsisting on the Closing Date; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(viii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>all other properties, assets and rights (tangible or intangible) of Seller (and its Affiliates) reasonably necessary to
conduct the Business as conducted during the Reference Period, other than any properties, assets or rights that are addressed by
the subject matter of clauses (i) through (vii) of this <U>Section 2.2(a)</U> or clauses (i) through (vii) of <U>Section 2.2(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Buyer acknowledges that the Purchased Assets shall consist only of those assets described in <U>Section 2.2(a)</U> and all
other assets of Seller and its Affiliates are excluded (collectively, the &ldquo;<U>Excluded Assets</U>&rdquo;). The Excluded Assets
shall include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>all cash and cash equivalents of Seller;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>all Contracts other than the Assumed Contracts;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>all rights and claims of Seller to the extent relating to any Excluded Asset or any Excluded Liability, and all Tax and
other credits of Seller;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>all land, buildings and improvements (and all furniture, fixtures and equipment thereon or therein) owned or leased by Seller;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>subject to the IP License Agreement, all Trade Secrets and know-how related to Seller&rsquo;s true human antibody discovery
platform that do not constitute Seller Intellectual Property;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>subject to the IP License Agreement and the Clinical Manufacturing Agreement, all Trade Secrets and know-how related to
Seller&rsquo;s proprietary manufacturing technology that do not constitute Seller Intellectual Property;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(vii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>subject to the Clinical Manufacturing Agreement, all Inventory; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(viii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>except to the extent included in the Purchased Assets, all other properties, assets, goodwill and rights of Seller of whatever
kind and nature, real, personal or mixed, tangible or intangible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 2.3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Assumed Liabilities; Excluded Liabilities</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Pursuant to the terms and subject to the conditions of this Agreement, at the Closing, Seller shall, and shall cause its
Affiliates to, sell, convey, deliver, transfer and assign to Buyer (or its designated Affiliate), and Buyer (or its designated
Affiliate) shall assume from Seller and its applicable Affiliates the Assumed Liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Notwithstanding anything in this Agreement or the Related Documents to the contrary, other than the Assumed Liabilities,
Buyer shall not be the successor to Seller or any of its Affiliates, and Buyer expressly does not assume and shall not become liable
to pay, perform or discharge, any Liability whatsoever of Seller or any of its Affiliates (including, for the avoidance of doubt,
any Liability arising out of or otherwise relating in any way to the Purchased Assets), other than the Assumed Liabilities. All
such Liabilities are referred to herein as the &ldquo;<U>Excluded Liabilities</U>&rdquo;. Seller shall, or shall cause its Affiliates
to, pay, perform and discharge when due all of the Excluded Liabilities. Without limitation of the foregoing, the Excluded Liabilities
shall include the following Liabilities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any Liabilities relating to or arising out of the Excluded Assets;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any Liabilities relating to or arising out of Accounts Payable (other than the Assumed Liabilities);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any Excluded Taxes;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any Liabilities to present or former members or shareholders of Seller or any of its Affiliates;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any Liabilities of Seller or any of its Affiliates under this Agreement, the Related Documents or in connection with the
Contemplated Transactions;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>all Liabilities under any Contract (other than the Assumed Liabilities);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(vii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>all Liabilities under all Business Employee Benefit Plans;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(viii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>all Liabilities arising out of the employment or service or termination of employment or service of any employee, officer,
director or manager or consultant of Seller or any of its Affiliates, whether or not any such Liabilities are claimed or otherwise
arise prior to or after the Closing, other than, in the case of Transferred Business Employees, any such Liabilities that arise
after the applicable Transfer Time;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(ix)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any Liabilities (including all Actions relating to such Liabilities) of Seller or any of its Affiliates to any Person and
claims from any Person relating to or arising out of circumstances existing on or prior to the Closing, including those relating
to or arising out of any product liability, patent infringement, breach of warranty or similar claim for injury to person or property
that resulted from the use, operation, ownership or misuse of the Purchased Assets or the operation of the business of Seller or
any of its Affiliates, including the conduct of the Business, to the extent such conduct occurred on or prior to the Closing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(x)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any Liabilities (including all Actions relating to such Liabilities) from or relating to the Intellectual Property Rights
of any Person on or prior to the Closing, including any Liability for any loss or infringement, dilution, misappropriation, other
violation thereof or for violation of privacy, personal information or data protection rights that resulted from the use, operation,
ownership or misuse of the Purchased Assets or the operation of the business of Seller or any of its Affiliates, including the
conduct of the Business, to the extent such conduct occurred on or prior to the Closing; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(xi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any other Liabilities arising out of the Purchased Assets or the operation of the business of Seller or any of its Affiliates
on or prior to the Closing, whether or not any such Liabilities are claimed or otherwise arise prior to or after the Closing (other
than the Assumed Liabilities).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 2.4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Closing; Closing Deliverables</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Closing</U>. The closing of the Contemplated Transactions (the &ldquo;<U>Closing</U>&rdquo;) shall take place remotely,
by exchange of electronic copies of the agreements, documents, certificates and other instruments set forth in this <U>Section&nbsp;2.4</U>,
at 10:00 a.m., New York City time, on the second Business Day following the satisfaction (or, to the extent permitted, waiver)
of the conditions set forth in <U>Article VI</U> (other than those conditions that by their terms are to be satisfied or waived
at the Closing, but subject to the satisfaction or waiver of such conditions), or at such other place, time and date as shall be
agreed between Buyer and Seller. The date on which the Closing occurs is referred to herein as the &ldquo;<U>Closing Date</U>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Seller Closing Deliverables</U>. At the Closing, Seller shall deliver or cause to be delivered to Buyer:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the Bill of Sale, Assignment and Assumption Agreement, substantially in the form of <U>Exhibit 2.4(b)(i)</U> (the &ldquo;<U>Bill
of Sale, Assignment and Assumption Agreement</U>&rdquo;), duly executed by Seller and/or XBiotech USA, Inc. (&ldquo;<U>XBiotech
USA</U>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the Escrow Agreement among Seller, Buyer and the Escrow Agent, substantially in the form of <U>Exhibit 2.4(b)(ii)</U> (the
&ldquo;<U>Escrow Agreement</U>&rdquo;), duly executed by Seller and the Escrow Agent;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>a Patent Assignment Agreement, substantially in the form of <U>Exhibit 2.4(b)(iii)</U> (the &ldquo;<U>Patent Assignment
Agreement</U>&rdquo;), duly executed by Seller and/or XBiotech USA;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>a Clinical Manufacturing Agreement, substantially in the form of <U>Exhibit 2.4(b)(iv)</U> (the &ldquo;<U>Clinical Manufacturing
Agreement</U>&rdquo;), duly executed by XBiotech USA;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>a License to Occupy, substantially in the form of <U>Exhibit 2.4(b)(v)</U> (the &ldquo;<U>License to Occupy</U>&rdquo;),
duly executed by XBiotech USA;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>a Transition Services Agreement, substantially in the form of <U>Exhibit 2.4(b)(vi)</U> (the &ldquo;<U>Transition Services
Agreement</U>&rdquo;), duly executed by XBiotech USA;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(vii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>an IP License Agreement, substantially in the form of <U>Exhibit 2.4(b)(vii)</U> (the &ldquo;<U>IP License Agreement</U>&rdquo;),
duly executed by Seller;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(viii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>a duly completed and accurate IRS Form W-9 or applicable IRS Form W-8; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(ix)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>evidence, acceptable to Buyer in its sole discretion, that all Liens set forth on <U>Schedule&nbsp;3.4(a)</U> have been
properly terminated or released on or before the Closing, including either (i)&nbsp;a completed UCC-3 Termination Statement, in
a proper form for filing, in respect of each such Lien, or (ii)&nbsp;a payoff letter from the secured party thereunder, in form
and substance acceptable to Buyer, certifying that upon receipt by or on behalf of Seller of the amount specified in such payoff
letter, such Lien shall be released with no further action and that such secured party will, promptly upon receipt of the specified
amount, deliver to Buyer a duly executed UCC-3 Termination Statement, in a proper form for filing, in respect of such Lien.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Buyer Closing Deliverables</U>. At the Closing, Buyer shall deliver or cause to be delivered to Seller:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the payments required pursuant to <U>Section 2.1(b)(i)</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the Bill of Sale, Assignment and Assumption Agreement, duly executed by Buyer and/or its applicable Affiliates;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the Escrow Agreement, duly executed by Buyer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the Patent Assignment Agreement, duly executed by Buyer and/or its applicable Affiliates;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the Clinical Manufacturing Agreement, duly executed by an Affiliate of Buyer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the License to Occupy, duly executed by an Affiliate of Buyer;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(vii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the Transition Services Agreement, duly executed by an Affiliate of Buyer; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(viii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the IP License Agreement, duly executed by Buyer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 2.5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Milestone Payments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Subject to the terms and conditions of this Agreement, and in further consideration of the sale, conveyance, delivery, transfer
and assignment of the Purchased Assets to Buyer and Seller&rsquo;s other covenants and obligations hereunder, Buyer shall pay,
or cause to be paid, a milestone payment of $150,000,000 to Seller upon Buyer or its Affiliates (or any of their respective licensees)
obtaining, prior to the date that is <B>[*****]</B> years following the Closing Date, the Required Commercialization Authorizations
for a Product for use in any Non-Dermatological Indication in (A) the <B>[*****]</B> or (B) <B>[*****]</B> of the <B>[*****]</B>
(each, a &ldquo;<U>Milestone Payment</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Notwithstanding anything to the contrary set forth in <U>Section 2.5(a)</U>, Seller shall be eligible to earn up to a maximum
of four Milestone Payments, for a maximum of $600,000,000. In no event shall Buyer be obligated to make Milestone Payments in excess
of $600,000,000 or to make any Milestone Payment in respect of activities occurring on or after the date that is <B>[*****]</B>
years following the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Buyer shall notify Seller in writing within <B>[*****]</B> Business Days after the achievement of a milestone described
in <U>Section&nbsp;2.5(a)</U> above by Buyer or any of its Affiliates (or any of their respective licensees), and Buyer shall pay
Seller a Milestone Payment no earlier than <B>[*****]</B> days and no later than <B>[*****]</B> days after such notification to
Seller. Payment of any Milestone Payment to Seller shall be made by wire transfer of immediately available funds to the account
set forth on <U>Schedule&nbsp;2.1(b)(i)</U> (or as otherwise directed by Seller in writing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Upon the payment of any Milestone Payment, the Non-Dermatological Indication in respect of which such Milestone Payment
was paid shall be deemed to be a Specified Indication; <U>provided</U> that, at any time following the delivery of a notice in
respect of a Milestone Payment described in <U>Section 2.5(c)</U> and prior to the payment of such Milestone Payment, Seller may
elect, by written notice to Buyer, to waive its right to such Milestone Payment, in which case (i) the Non-Dermatological Indication
in respect of which such Milestone Payment would have been payable shall not be deemed to be a Specified Indication and (ii) such
waived and unpaid Milestone Payment shall otherwise be deemed to have been paid and shall be counted as one of the four Milestone
Payments that Seller is eligible to earn.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">[*****] Text omitted
for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively
harmful if publicly disclosed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Notwithstanding anything to the contrary set forth in this <U>Section&nbsp;2.5</U>, it is the intention of the Parties that
the Exploitation of the Compound shall be exercised by Buyer and its Affiliates in accordance with their own business judgment
and in their sole and absolute discretion. Accordingly, the following shall apply (and Seller hereby acknowledges, understands
and agrees as follows):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Buyer and its Affiliates shall have complete control and sole discretion with respect to decisions concerning the Exploitation
of the Compound and such control and discretion by Buyer and its Affiliates could result in Seller receiving no Milestone Payment
whatsoever;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>neither Buyer nor any of its Affiliates has any duty to Exploit the Compound, to exert any level of efforts in Exploiting
the Compound or to achieve the milestone described in <U>Section&nbsp;2.5(a)</U> above;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>whether or not Buyer or any of its Affiliates Exploit the Compound, neither Buyer nor any of its Affiliates is prohibited
from Exploiting any other compounds or products that may compete with the Compound, or prioritizing other compounds or products
over the Compound;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>in making decisions regarding the Exploitation of the Compound, personnel of Buyer and its Affiliates are not required to
take into account the interests of Seller; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Seller shall not challenge in any Action any decision to, or not to, Exploit the Compound made by any director, officer,
employee or agent of Buyer or any of its Affiliates, unless such Action is in respect of a breach by Buyer of any of its express
obligations to make a Milestone Payment under this <U>Section 2.5</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 2.6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Third Party Consents</U>. If the assignment or transfer of any asset included in the Purchased Assets or any claim, right
or benefit arising thereunder or resulting therefrom, without the consent of a Third Party, would constitute a breach or other
contravention of the rights of such Third Party, would be ineffective with respect to any party to an agreement concerning such
asset, claim, right or benefit, or, upon assignment or transfer, would in any way adversely affect the rights of Seller or, upon
transfer, Buyer (each, a &ldquo;<U>Non-Assignable Right</U>&rdquo;), then Seller shall use its commercially reasonable efforts,
at Seller&rsquo;s sole cost and expense, to obtain such consent after the execution of this Agreement until such consent is obtained.
If any such consent cannot be obtained prior to the Closing and the Closing occurs, then, notwithstanding anything to the contrary
in this Agreement or any Related Document, (a) this Agreement and the related instruments of transfer shall not constitute an assignment
or transfer of the applicable Non-Assignable Right until and unless such consent is obtained (at which point such Non-Assignable
Right will be deemed to have been assigned or transferred under this Agreement on such date (the &ldquo;<U>Transfer Date</U>&rdquo;)),
and Seller shall use its commercially reasonable efforts, at Seller&rsquo;s sole cost and expense, to obtain such consent as soon
as possible after the Closing; and (b) upon delivery of Buyer&rsquo;s written election to Seller, (i) the Non-Assignable Right
shall be an Excluded Asset and Buyer shall have no Liability whatsoever with respect to any such Non-Assignable Right or any Liability
with respect thereto (and any consent to transfer or assignment obtained thereafter shall have no effect) or (ii) Seller shall,
at its sole cost and expense, obtain for Buyer substantially all of the practical benefit and burden of such Non-Assignable Right,
including by (A) entering into appropriate and reasonable alternative arrangements on terms mutually agreeable to Buyer and Seller,
(B) subject to the consent and control of Buyer, enforcement, at the cost and for the account of Buyer, of any and all rights of
Seller against the other party thereto arising out of the breach or cancellation thereof by such other party or otherwise and (C)
continuing to comply with, and perform, any contractual obligations associated with such Non-Assignable Right. For the avoidance
of doubt, nothing in this <U>Section 2.6</U> shall affect any determination as to whether any of the conditions set forth in <U>Article
VI</U> have been satisfied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 2.7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Escrow Amount</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In accordance with <U>Section&nbsp;2.1(b)(i)</U>, at the Closing, Buyer shall deposit with JPMorgan Chase Bank, National
Association (the &ldquo;<U>Escrow Agent</U>&rdquo;), an amount equal to the Escrow Amount, such amount plus all accumulated earnings
thereon (such amounts, if any, &ldquo;<U>Escrow Consideration</U>&rdquo;) to constitute an escrow fund (the &ldquo;<U>Escrow Fund</U>&rdquo;)
to be governed in accordance with the terms of this Agreement and the Escrow Agreement. The Escrow Fund may be used to satisfy
any indemnification amounts owed by Seller pursuant to <U>Article&nbsp;VII</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Upon the date that is 18 months from the Closing (the &ldquo;<U>Escrow Termination Date</U>&rdquo;), the Escrow Agent shall,
in accordance with the Escrow Agreement, release the remaining amount in the Escrow Fund at such time, less the Outstanding Claim
Reserve at such time, to Seller. If, at any time after the Escrow Termination Date, the Outstanding Claim Reserve, as determined
by Buyer in good faith, by a court or by mutual agreement of Buyer and Seller, is less than the Escrow Fund at such time, then
an amount equal to such difference shall be released to Seller.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>For purposes of this <U>Section 2.7</U>, &ldquo;<U>Outstanding Claim Reserve</U>&rdquo; as of any date means the sum of
all amounts claimed by Buyer as of such date to be then owed to the Buyer Indemnified Parties in respect of indemnity claims made
by the Buyer Indemnified Parties as of such date in accordance with <U>Article&nbsp;VII</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>All funds so released from the Escrow Fund shall include any Escrow Consideration earned thereon. The amount of any funds
released from the Escrow Fund pursuant to <U>Section&nbsp;2.7(b)</U> shall, for the avoidance of doubt, be deemed a part of the
Purchase Price to the extent permitted by applicable Law. The Escrow Fund shall be held as a trust fund and shall not be subject
to any Lien, and shall be held and disbursed solely for the purposes and in accordance with the terms of this Agreement and the
Escrow Agreement. Upon the final release of all of the Escrow Fund, the Escrow Agreement shall terminate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><B>ARTICLE
III</B><BR>
<BR>
<B>Representations and Warranties of Seller</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Subject to the Schedules
attached hereto (to the extent any such Schedule is numbered to correspond to a representation or warranty), Seller represents
and warrants to Buyer as set forth in this <U>Article III</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 3.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Organization, Standing and Power</U>. Seller is a corporation, duly organized, validly existing and in good standing
under the laws of the Province of British Columbia, and has all requisite corporate power and authority to own, lease or otherwise
hold and operate its properties and other assets and to carry on its business as presently conducted, except where the failure
to be in good standing or have such power or authority, individually or in the aggregate, has not been and would not reasonably
be expected to be material to Seller or the Business. Seller and each of its Affiliates is duly qualified or licensed to do business
and is in good standing (in jurisdictions that recognize the concept of good standing) in each jurisdiction in which the nature
of its business or the ownership, leasing or operation of its properties makes such qualification or licensing necessary, other
than in such jurisdictions where the failure to be so qualified or licensed or to be in good standing individually or in the aggregate
has not been and would not reasonably be expected to be material to Seller or the Business. Seller has made available to Buyer,
prior to the execution of this Agreement, complete and accurate copies of Seller&rsquo;s articles (&ldquo;<U>Seller&rsquo;s Charter</U>&rdquo;),
as amended to the date hereof. Seller is not in violation of any of the provisions of Seller&rsquo;s Charter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 3.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Authority; Noncontravention</U>. (a) Seller has all requisite corporate power and authority to execute and deliver this
Agreement and the Related Documents and to consummate the Contemplated Transactions. The execution and delivery of this Agreement
and the Related Documents by Seller and the consummation by Seller of the Contemplated Transactions have been duly authorized by
all necessary corporate action on the part of Seller and no other corporate proceedings on the part of Seller or any of its Affiliates
are necessary to authorize this Agreement, the Related Documents or to consummate the Contemplated Transactions. Each of this Agreement
and the Related Documents has been duly executed and delivered by Seller and, assuming the due authorization, execution and delivery
by Buyer, constitutes a legal, valid and binding obligation of Seller, enforceable against Seller in accordance with its terms,
subject to bankruptcy, insolvency, moratorium, reorganization or similar Laws affecting the rights of creditors generally and the
availability of equitable remedies. No stockholder or other equity holder approval is required on behalf of Seller for the execution,
delivery or performance of this Agreement or any Related Document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The execution and delivery of this Agreement and the Related Documents by Seller do not, and the consummation of the Contemplated
Transactions and compliance by Seller with the provisions of this Agreement and the Related Documents will not, conflict with,
or result in any violation or breach of, or default under (with or without notice or lapse of time, or both), or give rise to a
right of, or result in, termination, cancellation or acceleration of any obligation or to the loss of a benefit under, or result
in the creation of any Lien in or upon the Purchased Assets under, (i)&nbsp;Seller&rsquo;s Charter, (ii)&nbsp;any Contract to which
Seller or any of its Affiliates is a party or to which any of the Purchased Assets are subject or (iii) any (A)&nbsp;statute, ordinance,
rule, regulation or other Law applicable to Seller, any of its Affiliates or the Business or (B)&nbsp;Order applicable to Seller,
any of its Affiliates or the Business, except in the cases of clauses (ii) and (iii), where the conflict, violation, breach, default,
termination, cancellation, acceleration or creation of a Lien, individually or in the aggregate, has not been and would not reasonably
be expected to be material to Seller or the Business, or that would not reasonably be expected to prevent, materially impede or
materially delay the consummation by Seller of the Contemplated Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>No consent, approval, Order or authorization of, action by or in respect of, or registration, declaration or filing with,
any Governmental Authority (each, a &ldquo;<U>Governmental Consent</U>&rdquo;) is required by or with respect to Seller, any of
its Affiliates or the Business in connection with the execution and delivery of this Agreement or any Related Document by Seller,
the transfer of the Purchased Assets to Buyer or the consummation of the Contemplated Transactions, except for (i) such consents,
approvals, Orders, authorizations, actions, registrations, declarations or filings the absence of which, individually or in the
aggregate, would not reasonably be expected to be material to Seller or the Business, (ii) filing assignments with respect to registered
Patents, Trademarks and Copyrights and (iii) the receipt, termination or expiration, as applicable, of approvals or waiting periods
under any applicable antitrust, competition, fair trade or similar Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 3.3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Absence of Certain Changes or Events</U>. Since December 31, 2018 (a) no event has occurred which would reasonably be
expected to result in, individually or in the aggregate, a Material Adverse Effect, (b) there has been no material loss, destruction
or damage (in each case, whether or not insured) affecting the Business and (c) Seller and its Affiliates have conducted activities
with respect to the Business in the ordinary course of business consistent with past practice and have not taken any actions, which,
if taken after the date of this Agreement and prior to the Closing Date would constitute a breach of <U>Section 5.1(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 3.4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Good Title; Sufficiency of Assets</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>(i)&nbsp;Seller (together with its Affiliates) has good and marketable title to, or valid contract rights to, as applicable,
all of the Purchased Assets free and clear of all Liens (other than Permitted Liens), and has the complete and unrestricted power
and unqualified right to sell, assign, transfer and deliver to Buyer, as applicable, the Purchased Assets and (ii)&nbsp;there are
no adverse claims of ownership to the Purchased Assets and neither Seller nor any of its Affiliates has received notice that any
Person has asserted a claim of ownership or right of possession or use in or to any of the Purchased Assets, nor are there, to
Seller&rsquo;s Knowledge, any facts, circumstances or conditions on which any such claim could be brought in the future. At the
Closing, Buyer will acquire from Seller (and its Affiliates) good and marketable title to, or valid contract rights to, as applicable,
all of the Purchased Assets, free and clear of all Liens (other than Permitted Liens).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Except as set forth on <U>Schedule 3.4(b)</U>, the Purchased Assets, together with the Intellectual Property Rights licensed
pursuant to the IP License Agreement, constitute (i)&nbsp;all of the properties, interests, assets and rights of Seller or any
of its Affiliates acquired, conceived, collected, compiled, generated, reduced to practice or otherwise made or used in connection
with the Compound Program and (ii) all of the properties, interests, assets and rights of Seller or any of its Affiliates used,
held for use or intended to be used in connection with the Compound Program or the Compound, in each case that are reasonably necessary
for Buyer and its Affiliates to continue to conduct the Compound Program as conducted during the Reference Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 3.5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Intellectual Property</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Subject to <U>Sections 3.5(b)</U> and <U>3.5(f)</U>, Seller (together with its Affiliates) exclusively owns, or validly
Controls, all Seller Intellectual Property (including all Intellectual Property Rights set forth on <U>Schedule&nbsp;1.1(d)</U>),
in each case free and clear of all Liens (other than Permitted Liens). Each such Intellectual Property Right will, immediately
subsequent to the Closing, be transferred to, and Controlled by, Buyer on the same terms with which Seller (or its applicable Affiliate),
immediately prior to the Closing, Controlled such Intellectual Property Right (subject to the effect of the IP License Agreement).
Other than as set forth on <U>Schedule 1.1(d)</U>, there are no Trademarks, Copyrights or Software that are owned or Controlled
by Seller and primarily related to or reasonably necessary to conduct the Business as conducted during the Reference Period. Seller
and its Affiliates have used reasonable efforts to make all filings with Governmental Authorities and obtain all grants and registrations
as may be necessary or appropriate to preserve and protect the Seller Intellectual Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To Seller&rsquo;s Knowledge, neither Seller nor any of its Affiliates has infringed, diluted, misappropriated or otherwise
violated or is infringing, diluting, misappropriating or otherwise violating&nbsp;(including with respect to the discovery, development,
clinical testing, manufacture, distribution, advertising, use, Exploitation or sale by Seller or any of its Affiliates of the Compound)
the rights of any other Person with regard to Seller&rsquo;s or its Affiliates&rsquo; possession, use or Control of any Seller
Intellectual Property for the Business as conducted during the Reference Period. To Seller&rsquo;s Knowledge, no other Person or
Persons has infringed, diluted, misappropriated or otherwise violated or is or are infringing, diluting, misappropriating or otherwise
violating the Seller Intellectual Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Seller Intellectual Property is, to Seller&rsquo;s Knowledge, enforceable and valid, and no claims against Seller or
any of its Affiliates are pending or, to Seller&rsquo;s Knowledge, threatened with regard to (i) the Control or use of any Seller
Intellectual Property; (ii) any actual or potential infringement, dilution, misappropriation or unauthorized use of Seller Intellectual
Property; (iii) any actual or potential infringement, dilution, misappropriation or unauthorized use of any Third Party&rsquo;s
Intellectual Property Rights with respect to any Seller Intellectual Property or the Business; or (iv) the validity or enforceability
of any Seller Intellectual Property. Seller (or its applicable Affiliate) has the right to bring actions for infringement, including
all rights to recover damages for past infringement (to the extent permitted by applicable Law), of all Seller Intellectual Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Schedule&nbsp;1.1(d)</U> sets forth, as of the date hereof, a complete and accurate list of all patents and applications
therefor (which list specifically identifies all patents and patent applications solely and exclusively owned by Seller and its
Affiliates), registered trademarks and applications therefor (if any), material common law trademarks, domain name registrations
(if any), copyright registrations (if any) and all invention disclosures, that, in each case, are Controlled by Seller and its
Affiliates and related to the Business. The&nbsp;patent applications listed in <U>Schedule 1.1(d)</U> that are owned by Seller
and its Affiliates are (and such applications that are otherwise Controlled by Seller and its Affiliates are, to Seller&rsquo;s
Knowledge) pending and have not been abandoned and have been and continue to be timely prosecuted except as otherwise set forth
in <U>Schedule 1.1(d)</U>. All patents, registered trademarks and applications therefor owned by Seller and its Affiliates that
are related to the Business have been (and all such patents, registered trademarks and applications otherwise Controlled by Seller
and its Affiliates have been to Seller&rsquo;s Knowledge) duly registered or filed with or issued by each appropriate Governmental
Authority in the jurisdiction indicated in <U>Schedule 1.1(d)</U>, all related necessary affidavits of continuing use have been
(or, with respect to licenses, to Seller&rsquo;s Knowledge have been) timely filed, and all related necessary maintenance fees
have been (or, with respect to licenses, to Seller&rsquo;s Knowledge have been) timely paid to continue all such rights in effect
except as otherwise set forth in <U>Schedule 1.1(d)</U>. None of the patents listed in <U>Schedule&nbsp;1.1(d)</U> that are owned
by Seller or its Affiliates has (and no such patents that are otherwise Controlled by Seller or its Affiliates have, to Seller&rsquo;s
Knowledge) expired, been disclaimed (except by terminal disclaimers), in whole or in part, been declared invalid, in whole or in
part, or held to be unenforceable by any Governmental Authority except as otherwise set forth in <U>Schedule 1.1(d)</U>. None of
the trademarks or trademark applications listed in <U>Schedule 1.1(d)</U> that are owned by Seller or its Affiliates are (and no
such trademarks or trademark applications that are otherwise Controlled by Seller or its Affiliates are to Seller&rsquo;s Knowledge)
involved in or the subject of any ongoing oppositions, cancellations or other proceedings. None of the patents or patent applications
listed in <U>Schedule 1.1(d)</U> that are owned by Seller or its Affiliates are (and no such patents or patent applications that
are otherwise Controlled by Seller or its Affiliates are, to Seller&rsquo;s Knowledge) involved in or the subject of any material
ongoing interferences, oppositions, reissues, reexaminations or other proceedings (except for appeals), including ex parte (other
than ex parte proceedings in connection with such patent applications) and post-grant proceedings, in the United States Patent
and Trademark Office or in any foreign patent office or similar administrative agency. To Seller&rsquo;s Knowledge, there are no
published patents, patent applications, articles or other prior art references that are likely to invalidate any patent listed
in <U>Schedule 1.1(d)</U>. Each of the patents and patent applications listed in <U>Schedule 1.1(d)</U> that are owned by Seller
and its Affiliates properly identifies (and, to Seller&rsquo;s Knowledge, such patents and applications otherwise Controlled by
Seller and its Affiliates properly identify) each and every inventor of the claims thereof as determined in accordance with the
Laws of the jurisdiction in which such patent is issued or such patent application is pending. Each inventor named on the patents
and patent applications listed in <U>Schedule&nbsp;1.1(d) </U>that are owned by Seller and its Affiliates has executed (and, to
Seller&rsquo;s Knowledge, such inventors named on such patents and applications that are otherwise Controlled by Seller and its
Affiliates and material to the Business have executed) an agreement assigning his, her or its entire right, title and interest
in and to such patent or patent application, and the inventions embodied and claimed therein, to Seller or an Affiliate of Seller,
or in the case of licensed Patents, to the appropriate owners. No such inventor has any contractual or other obligation that would
preclude any such assignment or otherwise conflict with the obligations of such inventor to Seller or an Affiliate of Seller under
such agreement with Seller or such Affiliate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>No current or former director, officer, employee, contractor or consultant of Seller or any of its Affiliates owns any rights
in or to any Seller Intellectual Property. All current and former directors, officers, employees, contractors and consultants of
Seller and any of its Affiliates who contributed to the Business or to the discovery, creation or development of any Seller Intellectual
Property did so (i) within the scope of his or her employment such that it constituted a work made for hire and all Seller Intellectual
Property arising therefrom became the exclusive property of Seller (or an Affiliate thereof) or (ii)&nbsp;pursuant to a written
agreement, assigned all of his or her rights in Seller Intellectual Property to Seller (or an Affiliate thereof). No current or
former directors, officers, employees, contractors or consultants of Seller or any of its Affiliates has made or threatened to
make any claim or challenge against Seller or any of its Affiliates in connection with their contribution to the Business or to
the discovery, creation or development of any Seller Intellectual Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Schedule&nbsp;3.5(f)</U> sets forth a complete and accurate list as of the date hereof of all options, rights, licenses
or interests of any kind relating to any Seller Intellectual Property, other than options, rights, licenses or interests pursuant
to the terms of the Assumed Contracts, that were (i) granted to Seller or any of its Affiliates by any other Person (other than
software licenses for commercially available off the shelf software and except pursuant to employee proprietary inventions agreements&nbsp;(or
similar employee agreements)), or (ii)&nbsp;granted by Seller or any of its Affiliates to any other Person&nbsp;(including any
obligations of such other Person to make any fixed or contingent payments, including royalty payments). All obligations for payment
of monies currently due and payable by Seller or any of its Affiliates and other material obligations in connection with such options,
rights, licenses or interests have been satisfied in a timely manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each of Seller and its Affiliates has used reasonable efforts and taken commercially reasonable steps designed to maintain,
preserve and protect its Trade Secrets and other confidential information acquired, conceived, developed, collected, compiled,
generated, reduced to practice or otherwise made or used in connection with or related to the Business, including through (1) the
development of a policy for the protection of Intellectual Property Rights, (2) requiring all employees of Seller and its Affiliates
to execute confidentiality agreements with respect to Intellectual Property Rights developed for or obtained from Seller and its
Affiliates and (3) entering into licenses and Contracts that generally require licensees, contractors and other Third Parties with
access to the Trade Secrets or other confidential information to keep such Trade Secrets or other confidential information confidential.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The execution and delivery of this Agreement and the Related Documents by Seller do not, and the consummation of the Contemplated
Transactions and compliance by Seller with the provisions of this Agreement and any Related Document will not, conflict with, or
result in any violation or breach of, or default&nbsp;(with or without notice or lapse of time, or both) under, or give rise to
a right of, or result in, termination, cancellation or acceleration of any right or obligation or to the loss of a benefit under,
or result in the creation of any Lien in or upon or the transfer of, any Seller Intellectual Property that is material to the Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Schedule 3.5(i)</U> accurately describes each development program conducted by Seller as of the date hereof with respect
to any monoclonal antibody other than bermekimab that targets human Interleukin 1 alpha (any such monoclonal antibody, an &ldquo;<U>Existing
Antibody</U>&rdquo;), none of which development programs were initiated prior to <B>[*****]</B>. Each Existing Antibody described
on <U>Schedule 3.5(i)</U> (i) was identified and developed as a result of a <I>de novo</I> discovery and development effort undertaken
by Seller or any of its Affiliates without the use of or reference to <B>[*****] </B>including by means of <B>[*****]</B> (ii)
qualifies as a new molecular entity under FDA regulations and guidelines and (iii) <B>[*****]</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Other than the Compound Program or any development program described on <U>Schedule 3.5(i)</U>, neither Seller nor any of
its Affiliates or, to Seller&rsquo;s Knowledge, any of its or their Third Party collaborators, has any development program that
produced any molecules that bind human Interleukin 1 alpha and have demonstrable biological activity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Neither Seller nor any of its Affiliates owns, Controls or has an interest in any monoclonal antibody that targets human
Interleukin 1 alpha other than the Compound or an Existing Antibody, with the exception of any non-human anti-human anti-IL-1a
antibody used for research purposes in which any such antibody was not administered to humans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Seller has disclosed to Buyer all Data and information relating to the Compound and any other monoclonal antibody that targets
human Interleukin 1 alpha in its ownership or Control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 3.6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Assumed Contracts</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>There are no Contracts, other than the Assumed Contracts (including any Contracts that become Assumed Contracts pursuant
to <U>Section 5.7(d)</U> following the date hereof) and the Excluded Contracts, (i) to which Seller or any of its Affiliates is
a party or by which Seller or any of its Affiliates is bound, in either case, that are primarily related or material to the Business
or (ii) to which any of the Purchased Assets are subject.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">[*****] Text omitted
for confidential treatment. The redacted information has been excluded because it is both (i) not material and (ii) would be competitively
harmful if publicly disclosed.<BR STYLE="clear: both">
</P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Seller has made available to Buyer true, accurate and complete copies of the Assumed Contracts (and any Contracts listed
on <U>Schedule 3.6(a)</U>), including all amendments, modifications and waivers relating thereto. The Assumed Contracts are legal,
valid and binding agreements of Seller or an Affiliate of Seller and are in full force and effect and are enforceable against Seller
or its applicable Affiliate and, to Seller&rsquo;s Knowledge, each other party thereto, in accordance with their terms, subject
to bankruptcy, insolvency, moratorium, reorganization or similar Laws affecting the rights of creditors generally and the availability
of equitable remedies. Seller or its applicable Affiliate has performed all obligations required to be performed by it to date
under the Assumed Contracts, and neither Seller nor its applicable Affiliate is or will be (with or without notice or lapse of
time, or both) in breach or default in any respect thereunder and, to Seller&rsquo;s Knowledge, no other party to any Assumed Contract
is or will be (with or without notice or lapse of time, or both) in breach or default in any respect thereunder. Neither Seller
nor any of its Affiliates has received any notice of intention to terminate any Assumed Contract or of any claim of breach with
respect to the performance of Seller&rsquo;s (or its applicable Affiliate&rsquo;s) obligations under any Assumed Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 3.7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Compliance with Law; Permits</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The business and operations of Seller and its Affiliates as such business and operations relate to the Business are and,
since January 1, 2015, have been conducted in compliance in all material respects with all applicable Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Seller and its Affiliates have and, since January 1, 2015, have had and maintained all material Permits necessary for such
business and operations, except where the failure to have such Permits individually or in the aggregate has not been and would
not reasonably be expected to be material to Seller or the Business. <U>Schedule 3.7(b)</U> sets forth a true, accurate and complete
list of each such Permit, and each such Permit is valid and in full force and effect. There has occurred no material default by
Seller or its Affiliates under, or material violation by Seller or its Affiliates of, any such Permit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Neither Seller nor any of its Affiliates has received any notice from any Governmental Authority or other Person to the
effect that Seller or its applicable Affiliate is not, or may not be, in compliance with any Law or any Permit in any material
respect with respect to the Business. No Action is pending or, to Seller&rsquo;s Knowledge, threatened to cancel, suspend, revoke
or limit any of the Permits and, to Seller&rsquo;s Knowledge, there is no basis for any such Action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 3.8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Litigation</U>. There is no Action pending or, to Seller&rsquo;s Knowledge, threatened before or by any Governmental
Authority that, if successful, could reasonably be expected to be materially adverse to the Business or could reasonably be expected
to result in restraining, enjoining or otherwise preventing the consummation by Seller of the Contemplated Transactions, nor are
there currently in existence, to Seller&rsquo;s Knowledge, any facts, circumstances or conditions reasonably likely to give rise
to any such Action in the future. There is no outstanding Order of any Governmental Authority against Seller or any of its Affiliates
arising out of or relating to the Business that could reasonably be expected to be materially adverse to the Business or that could
reasonably be expected to result in restraining, enjoining or otherwise preventing the consummation by Seller of the Contemplated
Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 3.9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Taxes</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>All Tax Returns required to be filed for any Pre-Closing Tax Period with respect to the Purchased Assets have been filed
when due in accordance with all applicable Laws. Each such Tax Return is complete and accurate in all respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>All Taxes required to be paid with respect to the Purchased Assets have been duly and timely paid in accordance with all
applicable Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>There are no Liens for Taxes on the Purchased Assets, except for statutory Liens for Taxes that are not yet due and payable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>No Taxing Authority has asserted an adjustment in writing that could result in the creation of a Lien on any of the Purchased
Assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>No Tax Return of any of Seller or any of its Affiliates to the extent related to the Purchased Assets is under audit or
examination by any Taxing Authority, and no such audit or examination has been threatened in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Seller and the Affiliates of Seller that own the Purchased Assets have complied in all respects with all applicable Laws
relating to the collection, payment and withholding of Taxes and has, within the time and manner prescribed by Law, collected,
withheld from and paid over to the appropriate Taxing Authority all amounts required to be so collected, withheld and paid over
under applicable Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Except as set forth on <U>Schedule 3.9(g)</U>, neither Seller nor any of its Affiliates that own the Purchased Assets is
a non-resident of Canada for purposes of the <I>Income Tax Act</I> (Canada). None of the Purchased Assets being sold by any entity
identified on <U>Schedule 3.9(g)</U> as being a non-resident of Canada constitutes &ldquo;taxable Canadian property&rdquo; for
purposes of the <I>Income Tax Act</I> (Canada).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 3.10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Employees and Employee Benefit Plans; Labor Relations.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Schedule 3.10(a)</U> sets forth a true, accurate and complete list as of the date hereof of each Business Employee Benefit
Plan. Seller has made available to Buyer, with respect to each Business Employee Benefit Plan as of the date hereof, (i) a true,
accurate and complete copy of all plan documents, if any, including related trust agreements, funding arrangements, and insurance
contracts and all amendments thereto and (ii) to the extent applicable, all current summary plan descriptions and summaries of
material modifications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each Business Employee Benefit Plan has been established, administered and maintained in accordance with its terms, and
in compliance with ERISA, the Code and all other applicable Laws, except as would not reasonably be expected to be materially adverse
to the Business or any Business Employee. All contributions in respect of the Business Employees required to have been made under
any of the Business Employee Benefit Plans to any funds or trusts established thereunder or in connection therewith have been made
or have been accrued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>With respect to the Business Employees, and other than as provided in the offers of employment described in <U>Section 5.10</U>,
neither the execution and delivery of this Agreement nor the consummation of the transactions contemplated by this Agreement will,
either alone or upon the occurrence of any additional or subsequent event, (i) cause any payments to become due or payable, (ii)
cause any acceleration, vesting or increase of compensation or benefits, or result in any payment or funding (through a grantor
trust or otherwise) of material compensation or benefits or (iii) result in any payment that would be considered an &ldquo;excess
parachute payment&rdquo; within the meaning of Section 280G of the Code. No Business Employee is entitled to any Tax gross-up,
make whole or similar payment with respect to any Taxes or penalties imposed under Sections 409A or 4999 of the Code or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>There are no pending or, to Seller&rsquo;s Knowledge, threatened, actions, claims or lawsuits against or relating to any
Business Employee Benefit Plan or any trusts related thereto with respect to the operation of such plan (other than routine benefits
claims) that, if successful, could reasonably be expected to be materially adverse to the Business or any Business Employee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Except as would not reasonably be expected to be materially adverse to the Business or any Business Employee, none of Seller,
any of its ERISA Affiliates nor any of their respective predecessors has, in the six years preceding the date of this Agreement,
sponsored, maintained or contributed to: (i) any plan that is or was subject to Title IV of ERISA; (ii) any &ldquo;multiple employer
welfare arrangement&rdquo; as defined in Section 3(40)(A) of ERISA or a &ldquo;voluntary employees&rsquo; beneficiary association&rdquo;
as defined in Section 501(c)(9) of the Code; or (iii) any &ldquo;multiemployer plan&rdquo; as defined in Section 4001(a)(3) of
ERISA, &ldquo;multiple employer plan&rdquo; as defined in 29 C.F.R. &sect;&nbsp;4001.2 or plan subject to Section 413(c) of the
Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Seller and its Affiliates do not have any current or projected liability in respect of, and do not sponsor or otherwise
provide any, post-employment or post-retirement health or medical or life insurance benefits for any Business Employee, except
as may be required by Section 4980B of the Code and Section 601 of ERISA or any other applicable Law or at the sole expense of
the Business Employee or the Business Employee&rsquo;s beneficiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Except as would not reasonably be expected to be materially adverse to the Business or any Business Employee, each Business
Employee Benefit Plan that is or forms part of a &ldquo;nonqualified deferred compensation plan&rdquo; within the meaning of Section
409A of the Code is in documentary compliance with the requirements of Section 409A of the Code, and Seller and its Affiliates
have complied in practice and operation with all applicable requirements of Section 409A of the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>For each Business Employee, <U>Schedule 3.10(h)</U> sets forth such Business Employee&rsquo;s name, job title, date of hire,
Fair Labor Standards Act designation (where relevant), work location (identified by street address), current compensation rate,
total incentive compensation paid for the prior year (including sales incentives and commissions), incentive compensation opportunity
for the current year (including sales incentives and commissions), all other wage arrangements, fringe benefits (other than employee
benefits generally applicable to all of the Seller&rsquo;s employees that are set forth on <U>Schedule 3.10(a)</U>), and visa and
green card application status or other relevant immigration application status.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>As of the date hereof, with respect to any Business Employee: (i) neither Seller nor any of its Affiliates is a party to
or subject to, or is currently negotiating in connection with entering into, any collective bargaining or other Contract with any
labor organization or representative and, to Seller&rsquo;s Knowledge, there has not been any other organizational campaign, petition
or other unionization activity seeking recognition of a collective bargaining unit or other labor organization or representative;
(ii) there is no labor strike, slowdown, stoppage, picketing, interruption of work or lockout pending or, to Seller&rsquo;s Knowledge,
threatened against Seller or any of its Affiliates; and (iii) there are no labor- or employment-related Actions, grievances, complaints
or other charges pending or, to Seller&rsquo;s Knowledge, threatened against Seller or any of its Affiliates by or before any Governmental
Authority that could reasonably be expected to be materially adverse to the Business or any Business Employee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>With respect to the Business Employees, Seller and its Affiliates are and at all times have been in material compliance
with, all applicable Laws governing the employment of labor and the engagement of other service providers, reporting to the IRS
and all other Governmental Authorities, and the paying and withholding of Taxes, including but not limited to, all contractual
commitments and all such Laws relating to wages, hours, the classification of service providers, immigration and employment verification
(including completion of Forms I-9), affirmative action, collective bargaining, discrimination, civil rights, safety and health,
workers&rsquo; compensation, reporting of compensation and benefits and the collection and payment of income, employment and other
Taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Since January 1, 2013, to Seller&rsquo;s Knowledge, no allegations or reports of sexual harassment or discrimination with
respect to a protected classification, including race and gender, have been made to Seller or any of its Affiliates against a Business
Employee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 3.11.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Regulatory Matters</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Schedule&nbsp;3.11(a)</U> sets forth as of the date hereof a true and complete list of all Seller Regulatory Authorizations.
The Seller Regulatory Authorizations include all material Regulatory Authorizations that are required for or primarily relate to
the conduct of the Business as presently conducted by Seller and its Affiliates. Seller or one of its Affiliates is the sole and
exclusive owner of all of the Seller Regulatory Authorizations and none of the Seller Regulatory Authorizations have been sold,
conveyed, delivered, transferred or assigned to another party. Each such Seller Regulatory Authorization (A) has, to Seller&rsquo;s
Knowledge, been validly issued or acknowledged by the appropriate Governmental Authority and is in full force and effect and (B)
is transferable to Buyer. To Seller&rsquo;s Knowledge, there are no facts, circumstances or conditions that would reasonably be
expected to prevent Seller from performing its obligations with respect to the transfer of any Seller Regulatory Authorization
to Buyer on or after the Closing Date, as provided in <U>Section 5.11</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Schedule 3.11(b)</U> sets forth a true and complete list of all pre-clinical and clinical studies, trials and investigations
conducted or sponsored by Seller or any of its Affiliates or, to Seller&rsquo;s Knowledge, by any other Person on or prior to the
date hereof in relation to the Business. Except as set forth on <U>Schedule 3.11(b)</U>, all pre-clinical and clinical studies,
trials and investigations conducted or sponsored by Seller or any of its Affiliates or, to Seller&rsquo;s Knowledge, by any other
Person in relation to the Business are being, and at all times have been, conducted in compliance in all material respects with
all then applicable clinical protocols, informed consents and then applicable Laws administered or issued by applicable Governmental
Authorities, including (to the extent applicable) (i) the U.S. Food and Drug Administration (&ldquo;<U>FDA</U>&rdquo;) or other
health authority standards for conducting non-clinical laboratory studies, including those contained in Title 21, part 58 of the
Code of Federal Regulations and associated regulatory guidance, (ii) investigational new drug requirements and associated regulatory
guidance, (iii) FDA or other health authority standards for the design, conduct, performance, monitoring, auditing, recording,
analysis and reporting of clinical trials, including those contained in Title 21, parts 50, 54, 56, 312, 314, 320 and 601 of the
Code of Federal Regulations and associated regulatory guidance, and (iv) the International Conference on Harmonisation Guideline
on Good Clinical Practice (ICH Topic E6) and associated regulatory guidance. Except as set forth on <U>Schedule 3.11(b)</U>, there
have been no drug-related, adverse event or events in patients in a clinical trial conducted or sponsored in relation to the Business,
the effect of which could reasonably be expected to prevent or materially delay Buyer from obtaining approval from a Governmental
Authority to market a Product in the United States. All clinical trial adverse events in patients in a clinical trial conducted
or sponsored in relation to the Business, to Seller&rsquo;s Knowledge, have been disclosed to Buyer and all associated correspondence,
including actual or potential claims for recompense, have been made available to Buyer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Schedule 3.11(c)</U> sets forth a true, accurate and complete copy of Seller&rsquo;s budget for the Specified Clinical
Trials (as defined in the Transition Services Agreement), which such budget has been prepared by Seller in good faith, based on
reasonable estimates and assumptions made by the management of Seller.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>No Governmental Authority has commenced, or, to Seller&rsquo;s Knowledge, threatened to initiate, any Action to place a
clinical hold order on, or otherwise terminate, delay or suspend any proposed or ongoing pre-clinical or clinical studies, trials,
investigational new drug application or investigations conducted or proposed to be conducted in connection with the Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Seller and its Affiliates have not received any oral or written communication (including any warning letter, untitled letter,
Form 483 or similar notice) from any Governmental Authority, and to Seller&rsquo;s Knowledge there are no material Actions related
to the Business pending or threatened (including any prosecution, injunction, seizure, civil fine, suspension or recall), in each
case (i) relating to, arising under or alleging that Seller, any of its Affiliates or any of its or their officers, employees or
agents is not currently in compliance with, any Law administered or issued by any Governmental Authority or (ii) regarding any
debarment action or investigation in respect of Seller, any of its Affiliates or any of its or their officers, employees or agents
undertaken pursuant to 21 U.S.C. Sections 335(a), (b) and (c), or any similar regulation of a Governmental Authority. There are
no pending voluntary or involuntary destruction orders, seizures or other regulatory enforcement actions related to the Business
and, to Seller&rsquo;s Knowledge, no Data relating to the Compound that has been made public is the subject of any regulatory or
other Action, either pending or threatened, by any Governmental Authority relating to the truthfulness or scientific adequacy of
such Data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Since January 1, 2017, none of Seller, its Affiliates nor, to Seller&rsquo;s Knowledge, any officer, employee, agent or
distributor of Seller or its Affiliates, has made an untrue statement of a material fact or fraudulent statement to the FDA or
any other Governmental Authority, failed to disclose a material fact required to be disclosed to the FDA or any other Governmental
Authority, or committed an act, made a statement, or failed to make a statement that, at the time such disclosure was made, would
reasonably be expected to provide a basis for the FDA to invoke its policy respecting &ldquo;Fraud, Untrue Statements of Material
Facts, Bribery, and Illegal Gratuities&rdquo;, set forth in 56 Fed. Reg. 46191 (September 10, 1991) or for any other Governmental
Authority to invoke any similar policy. None of Seller, its Affiliates nor, to Seller&rsquo;s Knowledge, any officer, employee
or agent of Seller or its Affiliates has been convicted of any crime or engaged in any conduct for which debarment is mandated
by or authorized by 21 U.S.C. Sections 335(a), (b) and (c) or any similar Laws. None of Seller, its Affiliates nor, to Seller&rsquo;s
Knowledge, any officer, employee or agent of Seller or its Affiliates has been convicted of any crime or engaged in any conduct
for which such Person could be excluded from participating in the Federal health care programs under Section 1128 of the Social
Security Act of 1935, as amended (the &ldquo;<U>Social Security Act</U>&rdquo;), or any similar Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Seller and its Affiliates are, and, since January 1, 2017, have been, in compliance with: (i)&nbsp;laws, regulations and
guidance pertaining to state and federal Anti-Kickback Statutes (42 U.S.C. &sect;&sect; 1320a-7b(b), et seq. and their implementing
regulations) and the related Safe Harbor Statutes; (ii) laws, regulations and guidance pertaining to submission of false claims
to governmental or private health care payors (31 U.S.C. &sect;&sect; 3729, et seq. and its implementing regulations); and (iii)
state laws and federal laws and regulations relating to providing and reporting of payments to health care professionals or health
care entities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>None of Seller or any of its Affiliates is a &ldquo;covered entity&rdquo; or a &ldquo;business associate&rdquo; pursuant
to the Health Insurance Portability and Accountability Act of 1996 (as those terms are defined in 45 C.F.R. &sect;160.103). With
regard to their activities related to the Purchased Assets, Seller and its Affiliates have complied in all material respects with
all other applicable Laws relating to the privacy and security of individually identifiable information, including the Federal
Trade Commission Act, the Children&rsquo;s Online Privacy Protection Act (COPPA), and similar Laws in any foreign jurisdiction
in which Seller or any of its Affiliates does business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 3.12.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Inventory</U>. <U>Schedule 3.12</U> sets forth the Inventory as of the date hereof. As of the date hereof, the ingredients,
intermediates, raw materials, components, consumables, finished product forms, work-in-progress materials and packaging materials
contained in the Inventory (a) are free from any material defect or deficiency, (b) are in good and usable condition in the ordinary
course of business and (c) meet or exceed all of the applicable requirements and specifications, including good manufacturing practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 3.13.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Relationships with Suppliers</U>. From January 1, 2017 to the date hereof, no supplier of the Compound that is material
to the Exploitation of the Compound has canceled or otherwise terminated, or provided notice to Seller of its intent, or, to Seller&rsquo;s
Knowledge, threatened, to terminate its relationship with Seller with respect to the Compound, or, from January 1, 2017 to the
date hereof, decreased or limited in any material respect, or provided notice to Seller of its intent, or, to Seller&rsquo;s Knowledge,
threatened, to decrease or limit in any material respect, its sales of the Compound to Seller. As of the date hereof, to Seller&rsquo;s
Knowledge, no supplier of the Compound that is material to the Exploitation of the Compound is subject to an ongoing audit by a
Governmental Authority of such supplier&rsquo;s facilities or manufacturing processes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 3.14.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Brokers and Other Advisors</U>. No broker, investment banker, financial advisor or other Person&nbsp;is entitled to any
broker&rsquo;s, finder&rsquo;s, financial advisor&rsquo;s or other similar fee or commission in connection with the Contemplated
Transactions based upon arrangements made by or on behalf of Seller or any of its Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 3.15.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Insurance</U>. Seller and its Affiliates maintain such policies of insurance relating to the Business as are sufficient
for compliance by Seller and its Affiliates with (i) all requirements of applicable Laws and (ii) all Assumed Contracts. Seller
and each of its Affiliates has complied in all material respects with the provisions of each such policy under which it is an insured
party. Neither Seller nor any of its Affiliates has been refused any insurance with respect to the Business, nor has its coverage
been limited by any insurance carrier to which it has applied for insurance or with which it has carried insurance. To Seller&rsquo;s
Knowledge, there are no existing claims under any insurance policy relating to the Business. No notice of cancellation or termination
has been received with respect to any insurance policy relating to the Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 3.16.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Adequate Consideration; Continued Solvency</U>. The consideration to be received by Seller under this Agreement constitutes
fair consideration and reasonable value for the Purchased Assets. Seller is (a)&nbsp;able to pay its debts as they become due,
and (b)&nbsp;solvent and will be solvent immediately following the Closing. Seller is not engaged in business or a transaction,
and it is not about to engage in business or a transaction, for which its remaining assets and capital are or will be insufficient.
Seller does not intend to incur, or believe that it will incur, Liabilities that would be beyond its ability to pay as such Liabilities
matured. Seller has not entered into this Agreement for the purpose of hindering, delaying or defrauding its creditors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 3.17.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Related Party Transactions</U>. <U>Schedule 3.17</U> describes any transaction between Seller or its Subsidiaries, on
the one hand, and any current partner, director, officer, employee, manager, member or significant stockholder of Seller, on the
other hand, in each case, related to the Business. No current partner, director, officer, employee, manager, member or significant
stockholder of Seller owns or has any interest in the Purchased Assets, other than any indirect interest arising in connection
with the ownership of Seller&rsquo;s securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 3.18.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Anticorruption Matters</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>None of Seller, any of its Affiliates or, to Seller&rsquo;s Knowledge, any of their respective Representatives, distributors,
sales intermediaries or other Third Parties acting on behalf of Seller or any of its Affiliates, in any way relating to the Business:
(i) has taken any action in violation of any applicable anticorruption Law, including the U.S. Foreign Corrupt Practices Act (&ldquo;<U>FCPA</U>&rdquo;)
(15 U.S.C. &sect; 78 dd-1 et seq.); or (ii) has corruptly, offered, paid, given, promised to pay or give, or authorized the payment
or gift of anything of value, directly or indirectly, to any &ldquo;Public Official&rdquo;, as defined in this <U>Section 3.18</U>,
for purposes of (A) influencing any act or decision of any Public Official in his official capacity; (B) inducing such Public Official
to do or omit to do any act in violation of his lawful duty; (C) securing any improper advantage; or (D) inducing such Public Official
to use his or her influence with a government, Governmental Authority, or commercial enterprise owned or controlled by any Governmental
Authority (including state-owned or controlled veterinary or medical facilities), in order to assist the Seller or any of its Affiliates
or any Person related in any way to the Business, in obtaining or retaining business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>None of the Seller&rsquo;s or any of its Affiliates&rsquo; officers, directors, employees or agents acting on behalf of
Seller are themselves Public Officials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>For purposes of this <U>Section 3.18</U>, &ldquo;<U>Public Official</U>&rdquo; means: (i) any officer, employee or representative
of any regional, Federal, state, provincial, county or municipal government or government department, agency, or other division;
(ii) any officer, employee or representative of any commercial enterprise that is owned or controlled by a government, including
any state-owned or controlled veterinary or medical facility; (iii) any officer, employee or representative of any public international
organization, such as the African Union, the International Monetary Fund, the United Nations or the World Bank; (iv) any person
acting in an official capacity for any government or Governmental Authority, enterprise, or organization identified above; and
(v) any political party, party official or candidate for political office.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To Seller&rsquo;s Knowledge, no investigation or review by any Governmental Authority with respect to the violation of any
applicable anticorruption Law, including the FCPA, relating to the Business, is pending, or threatened. Neither Seller nor any
of its Affiliates has received any notice from any Governmental Authority or other Person to the effect that Seller or its applicable
Affiliate is not, or may not be, in compliance with any applicable anticorruption Law, including the FCPA, relating to the Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Seller and its Affiliates have established and maintained an anticorruption compliance policy with respect to the Business
appropriate to ensure compliance with applicable anticorruption Laws, including the FCPA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 3.19.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Export Controls and Sanctions Matters</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>None of Seller, any of its Affiliates or, to Seller&rsquo;s Knowledge, any of their respective Representatives, distributors,
sales intermediaries or other Third Parties acting on behalf of Seller or any of its Affiliates, in any way relating to the Business,
has taken any action in violation of any applicable export control Law, trade or economic sanctions Law, or antiboycott Law, in
the United States or any other jurisdiction, including:&nbsp; the Arms Export Control Act (22 U.S.C.A. &sect; 2278), the Export
Administration Act (50 U.S.C. App. &sect;&sect; 2401-2420), the International Traffic in Arms Regulations (22 C.F.R. 120-130),
the Export Administration Regulations (15 C.F.R. 730 et seq.), the Office of Foreign Assets Control Regulations (31 C.F.R. Chapter
V), the Customs Laws of the United States (19 U.S.C. &sect; 1 et seq.), the International Emergency Economic Powers Act (50 U.S.C.
&sect; 1701-1706), the U.S. Commerce Department antiboycott regulations (15 C.F.R. 560), the U.S. Treasury Department antiboycott
requirements (26 U.S.C. &sect; 999), any other export control regulations issued by the agencies listed in Part 730 of the Export
Administration Regulations, or any applicable non-U.S. Laws of a similar nature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>None of Seller nor any Affiliate, director, officer, employee, distributor, agent, representative, sales intermediary
or other third party acting on behalf of the Seller or any of its Affiliates, in any way relating to the Business, is listed on
the U.S. Office of Foreign Assets Control &ldquo;Specially Designated Nationals and Blocked Persons&rdquo; or any other similar
sanctions list.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>All export licenses, license exceptions and other consents, notices, waivers, approvals, orders, authorizations,
registrations, declarations, classifications and filings required for the export, import and re-export of products, services, software
and technology related to the Business (&ldquo;Export Approvals&rdquo;) have been obtained; and no Export Approvals are required
by the Laws identified in Section 3.19(a) for continued export, reexport or import of the Purchased Assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
To Seller&rsquo;s Knowledge, </FONT>no investigation or review by any Governmental Authority with
respect to violation of the Laws identified in Section 3.19(a) or any other similar Law relating to the Business,
is pending, or threatened<FONT STYLE="color: red"><STRIKE>. </STRIKE></FONT>Neither Seller nor any of its Affiliates has received
any notice from any Governmental Authority or other Person to the effect that Seller or its applicable Affiliate is not, or may
not be, in compliance with any of the Laws identified in Section 3.19(a) or any other similar
Law relating to the Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Seller and its Affiliates have established and maintained a
compliance policy with respect to the Business appropriate to ensure compliance with the Laws identified in Section 3.19(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 3.20.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Other Representations and Warranties</U>. (A) EXCEPT FOR THE REPRESENTATIONS AND WARRANTIES SET FORTH IN THIS AGREEMENT,
NONE OF SELLER OR ANY OTHER PERSON HAS MADE OR MAKES ANY REPRESENTATION OR WARRANTY, WRITTEN OR ORAL, STATUTORY, EXPRESS OR IMPLIED,
AT COMMON LAW OR OTHERWISE, WITH RESPECT TO SELLER OR THE PURCHASED ASSETS; AND (B) NONE OF SELLER OR ANY OTHER PERSON HAS MADE
OR MAKES ANY REPRESENTATION OR WARRANTY, WRITTEN OR ORAL, STATUTORY, EXPRESS OR IMPLIED, AT COMMON LAW OR OTHERWISE, AS TO THE
ACCURACY, COMPLETENESS OR MATERIALITY OF ANY INFORMATION, DATA OR OTHER MATERIALS (WRITTEN OR ORAL) HERETOFORE FURNISHED TO BUYER
AND ITS REPRESENTATIVES BY OR ON BEHALF OF SELLER <FONT STYLE="text-transform: uppercase">and any information, documents or material
made available to Buyer in the Data Room, management presentations or in any other form in expectation of the contemplated transactions,
OTHER THAN (X) IN THE CASE OF CLAUSES (A) AND (B), IN THE CASE OF FRAUD, AND (Y) IN THE CASE OF CLAUSE (B), TO THE EXTENT ANY SUCH
INFORMATION, DATa OR MATERIAL IS ITSELF the SUBJECT OF A REPRESENTATION OR WARRANTY CONTAINED IN THIS AGREEMENT. Seller acknowledges
and agrees that none of buyer or any other person has made or makes any representation or warranty, written or oral, statutory,
express or implied, at common law or otherwise, with respect to Buyer except as set forth in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><B>ARTICLE
IV</B><BR>
<BR>
<FONT STYLE="font-variant: small-caps; text-transform: none"><B>R</B></FONT><B>epresentations and Warranties of Buyer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Buyer represents and
warrants to Seller as set forth in this <U>Article&nbsp;IV</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 4.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Organization, Standing and Power</U><I>.</I> Buyer is a corporation duly organized, validly existing and in good standing
under the laws of the Pennsylvania and has all requisite corporate power and authority to carry on its business as presently conducted,
except where the failure to be in good standing or have such power or authority, individually or in the aggregate, has not been
and would not reasonably be expected to be material to Buyer, taken as a whole. Buyer is duly qualified or licensed to do business
and is in good standing (in jurisdictions that recognize the concept of good standing) in each jurisdiction in which the nature
of its business or the ownership, leasing or operation of its properties makes such qualification or licensing necessary, other
than in such jurisdictions where the failure to be so qualified or licensed or to be in good standing, individually or in the aggregate,
has not been and would not reasonably be expected to be material to Buyer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 4.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Authority; Noncontravention</U>. (a) Buyer has all requisite corporate power and authority to execute and deliver this
Agreement and the Related Documents and to consummate the Contemplated Transactions. The execution and delivery of this Agreement
and the Related Documents by Buyer and the consummation by Buyer of the Contemplated Transactions have been duly authorized by
all necessary corporate action on the part of Buyer and no other corporate proceedings on the part of Buyer are necessary to authorize
this Agreement, the Related Documents or to consummate the Contemplated Transactions. Each of this Agreement and the Related Documents
has been duly executed and delivered by Buyer (or an Affiliate thereof) and, assuming the due authorization, execution and delivery
by Seller, constitutes a legal, valid and binding obligation of Buyer (or an Affiliate thereof), enforceable against Buyer (or
an Affiliate thereof) in accordance with its terms, subject to bankruptcy, insolvency, moratorium, reorganization or similar Laws
affecting the rights of creditors generally and the availability of equitable remedies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The execution and delivery of this Agreement and the Related Documents by Buyer do not, and the consummation of the Contemplated
Transactions and compliance by Buyer with the provisions of this Agreement and the Related Documents will not, conflict with, or
result in any violation or breach of, or default under&nbsp;(with or without notice or lapse of time, or both), or give rise to
a right of, or result in, termination, cancellation or acceleration of any obligation or to the loss of a benefit under, or result
in the creation of any Lien in or upon any of the properties or other assets of Buyer under (i)&nbsp;the certificate of incorporation
or bylaws of Buyer, (ii)&nbsp;any Contract to which Buyer is a party or any of its respective properties or other assets is subject,
or (iii)&nbsp;any (A)&nbsp;statute, ordinance, rule, regulation or other Law applicable to Buyer or its properties or other assets
or (B)&nbsp;Order applicable to Buyer or its properties or other assets, except in the cases of clauses (ii) and (iii), where the
conflict, violation, breach, default, termination, cancellation, acceleration or creation of a Lien, individually or in the aggregate,
would not reasonably be expected to prevent, materially impede or materially delay the consummation by Buyer of the Contemplated
Transactions (including the payments required to be made pursuant to <U>Article II</U>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>No Governmental Consent is required by or with respect to Buyer in connection with the execution and delivery of this Agreement
or any Related Document by Buyer or the consummation by Buyer of the Contemplated Transactions, except for the receipt, termination
or expiration, as applicable, of approvals or waiting periods required under any applicable antitrust, competition, fair trade
or similar Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 4.3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Capital Resources</U>. Buyer has immediately available funds sufficient to consummate the Contemplated Transactions (including
the payments required to be made pursuant to <U>Article II</U>) on the terms contemplated by this Agreement including the payment
of all fees and expenses payable by Buyer in connection with the Contemplated Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 4.4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Litigation</U>. There is no Action pending or, to the actual knowledge of Buyer&rsquo;s officers, threatened before or
by any Governmental Authority that, if successful, could reasonably be expected to result in restraining, enjoining or otherwise
preventing the consummation by Buyer of the Contemplated Transactions. There is no outstanding Order of any Governmental Authority
against Buyer that could reasonably be expected to result in restraining, enjoining or otherwise preventing the consummation by
Buyer of the Contemplated Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 4.5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Brokers and Other Advisors</U>. No broker, investment banker, financial advisor or other Person is entitled to any broker&rsquo;s,
finder&rsquo;s, financial advisor&rsquo;s or other similar fee or commission in connection with the Contemplated Transactions based
upon arrangements made by or on behalf of Buyer or any of its Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 4.6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Independent Investigation</U>. Buyer has conducted its own independent investigation, review and analysis of the Purchased
Assets and the Compound Program and acknowledges that it has been provided access to the personnel, properties, assets, premises,
books and records, and other documents and data of Seller and its Affiliates for such purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><B>ARTICLE
V</B><BR>
<BR>
<B>Additional Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 5.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Conduct of Business</U>. (a) Except as set forth on <U>Schedule 5.1</U>, from the date of this Agreement until the Closing
Date, Seller shall, and shall cause its Affiliates to, (A) maintain and preserve in all respects the Purchased Assets, (B) conduct
activities with respect to the Business in the ordinary course of business consistent with past practice and (C) comply in all
material respects with all Laws and Permits applicable to the Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Except as set forth on <U>Schedule 5.1</U> or as otherwise required by Law, without limiting the generality of the foregoing,
from the date of this Agreement until the Closing Date, Seller shall not, and shall cause its Affiliates not to (without the prior
written consent of Buyer, which shall not be unreasonably withheld, delayed or conditioned (it being understood that withholding,
delaying or conditioning consent for any of the actions specified in clauses (iii) or (xi) below shall not, under any circumstances,
be considered to be unreasonable)):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>(A) incur, create, assume or permit the incurrence, creation or assumption of any Lien (other than Permitted Liens) with
respect to the Purchased Assets, (B) dispose of any of the Purchased Assets, other than Biological Materials in the ordinary course
of business, (C) dispose of any of the Inventory, other than in the ordinary course of business or (D) waive, release, sell, assign,
encumber, impair, fail to diligently maintain, license or transfer any material right, title or interest in or to any Purchased
Asset;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>(A) sell, assign, license, grant any non-assertion covenant with respect to, encumber, impair, abandon, fail to diligently
maintain, transfer or otherwise dispose of, any Seller Intellectual Property, (B) amend, waive, cancel, permit to lapse, or modify
any of Seller&rsquo;s rights in or to the Seller Intellectual Property, or (C) disclose or agree to disclose to any Person, other
than Representatives of Buyer, any Trade Secrets or other confidential information used or held for use in connection with the
Business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>except as required by Law as a result of activities conducted by Seller prior to the date of this Agreement, (A) make any
submissions (other than filings with respect to Seller&rsquo;s Patents in the ordinary course of business consistent with past
practice) to any Governmental Authority relating to the Business, including with respect to the conduct or design of clinical trials
sponsored or proposed by Seller or any of its Affiliates involving the Compound or any Product, (B) make any submissions to, or
correspond with, any domestic or foreign institutional review board, privacy board or ethics committee regarding a clinical trial
sponsored or proposed by Seller or any of its Affiliates or involving the Compound or any Product, (C) publish any Data or the
results of any ongoing studies regarding the Compound or any Product, including the results of investigator-initiated studies or
(D) otherwise initiate, support, facilitate or encourage any further clinical study involving the Compound or any Product;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>compromise or settle any Action if the terms of such compromise or settlement would be binding on Buyer or any of its Affiliates,
or any Purchased Assets, after the Closing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>except as may be required under any Business Employee Benefit Plan as in effect on the date hereof or by applicable Law,
(A) grant to any Business Employee any increase in compensation or benefits or any new or additional compensation (including equity-based
awards), (B) enter into, adopt, amend or terminate any Business Employee Benefit Plan with respect to the Business Employees, including
any employment or severance agreement, (C) take any action to accelerate vesting or payment of, or otherwise fund or secure payment
of, any compensation payable to a Business Employee, (D) make any loans or cash advance to any Business Employees or (E) enter
into any collective bargaining or other Contract with any labor organization or representative that covers the Business Employees;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>(A) terminate any Business Employee other than for cause or due to death or disability or (B) alter the duties and responsibilities
or position of any Business Employee in a manner that would adversely impact such Business Employees&rsquo; knowledge of the Compound
Program, including the Compound and all Products and the potential Exploitation thereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(vii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>(A) terminate, amend or modify, or waive any material right under, or fail to perform in all material respects all obligations
under, any Assumed Contract, Permit or other document or instrument relating to or affecting the Business or (B) enter into any
material Contract, document or instrument relating to or affecting the Business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(viii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>to the extent any such action would result in a Tax Lien upon any of the Purchased Assets, (A) make, revoke or change any
material Tax election, (B) adopt or change any Tax accounting method or period, (C) file any amended Tax Return with respect to
a material amount of Taxes, (D) enter into any closing agreement or settlement with respect to a material amount of Taxes, (E)
settle any claim or assessment for a material amount of Taxes, (F) consent to any extension or waiver of the statute of limitations
period applicable to any such Tax claim or assessment or (G) surrender any right to claim a refund of a material amount of Taxes;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(ix)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>fail to maintain true, accurate and complete Books and Records;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(x)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>fail to keep in force and effect insurance in respect of the Purchased Assets comparable in amount and scope of coverage
to that maintained as of the date of this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(xi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>use or reference the Compound in connection with the development of any Existing Antibody or New Antibody; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(xii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>agree to or authorize, or commit to agree to or authorize, in writing or otherwise, any action that would conflict with
the obligations set forth in clauses (i) through (xi) above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 5.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Commercially Reasonable Efforts</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each of the Parties agrees to use its respective commercially reasonable efforts to take, or cause to be taken, all actions,
to file, or cause to be filed, all documents and to do, or cause to be done, all things necessary, proper or advisable to consummate
the Contemplated Transactions as promptly as practicable, including (i) the obtaining of all necessary Governmental Consents and
(ii) the execution and delivery of any additional documents or instruments necessary to consummate the Contemplated Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In connection with and without limiting the foregoing,&nbsp;Seller and Buyer shall (or shall cause their respective Affiliates
to) (i) make any appropriate filings, if necessary or advisable (in the opinion of Buyer), pursuant to any applicable antitrust,
competition, fair trade or similar Laws with respect to the Contemplated Transactions as promptly as practicable and (ii) supply
as promptly as practicable and advisable to the appropriate Governmental Authorities any additional information and documentary
material that may be requested pursuant to any such applicable antitrust, competition, fair trade or similar Laws. All antitrust
filings to be made shall be made in substantial compliance with the requirements of the applicable antitrust, competition, fair
trade or similar Laws, as applicable. Each Party shall cooperate with the other Party to the extent necessary to assist the other
Party or its applicable Affiliate in the preparation of such filing and to promptly amend or furnish additional information thereunder.
Each Party shall use commercially reasonable efforts to furnish to outside counsel for the other all information required for any
filing, form, declaration, notification, registration and notice, other than confidential or proprietary information not directly
related to the Contemplated Transactions, and to keep the other Party reasonably informed with respect to the status of each Governmental
Consent being sought in connection with the Contemplated Transactions and the material communications between such Party and the
applicable Governmental Authority. If any objections are raised or asserted with respect to the Contemplated Transactions under
applicable Law or if any Action is instituted (or threatened to be instituted) by any applicable Governmental Authority or any
private party challenging any of the Contemplated Transactions as being in violation of any applicable Law or which would otherwise
prevent, impede or delay the consummation of the Contemplated Transactions, the Parties shall use their commercially reasonable
efforts to resolve any such objections or Actions so as to permit consummation of the Contemplated Transactions as soon as reasonably
practicable. Nothing in this Agreement shall be deemed to require Buyer to agree to, or proffer to, divest, license or hold separate
any rights or other assets or any portion of any business of Buyer or any of its Affiliates or any of the Purchased Assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 5.3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Exclusivity</U>. From the date of this Agreement until the earlier of the Closing Date and the termination of this Agreement,
Seller shall not, and shall not permit any of its Affiliates or its or their Representatives to, directly or indirectly, solicit,
initiate, enter into or conduct discussions concerning, or exchange information (including by way of furnishing information concerning
Seller, its Affiliates or the Purchased Assets) or enter into any negotiations concerning, provide information regarding, respond
to any inquiries, or solicit, receive, entertain or agree to any proposals for, the acquisition, directly or indirectly, of any
of the Purchased Assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 5.4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Access and Information; Advice of Changes</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>From the date of this Agreement until the earlier of the Closing Date and the termination of this Agreement, Seller shall,
and shall cause its Affiliates to, provide Buyer, its Affiliates and its and their Representatives, upon reasonable notice, reasonable
access during normal business hours to the Books and Records, to the operations and properties related to the Purchased Assets
and to Representatives of the Sellers involved in the Business; <U>provided</U>, <U>however</U>, that Seller and its Affiliates
may withhold any document or information to the extent Seller believes in good faith, after consultation with counsel, that disclosure
of such document or information would (i) jeopardize the attorney-client privilege of such party or (ii) contravene any applicable
Laws; <U>provided</U> further that, in each case of clauses (i) and (ii), that Seller and its Affiliates will use commercially
reasonable efforts to provide such documents or information in a manner that does not so jeopardize attorney-client privilege or
contravene any applicable Law. Buyer acknowledges and agrees that any information provided to it or any of its Representatives
pursuant to this <U>Section 5.4</U> is subject to the confidentiality obligations set forth in the Confidentiality Agreement. If
any of the documents or information furnished pursuant to this <U>Section 5.4</U> includes documents or information subject to
the attorney-client privilege or attorney work-product doctrine or any other applicable privilege concerning pending or threatened
Actions or governmental investigations, each Party understands and agrees that the Parties have a commonality of interest with
respect to such matters, and it is the desire, intention and mutual understanding of the Parties that the sharing of such documents
or information is not intended to, and shall not, waive or diminish in any way the confidentiality of such documents or information,
nor its continued protection under the attorney-client protection, attorney work-product doctrine, or other applicable privilege,
and shall remain entitled to such protection under those privileges, this Agreement, and the joint defense doctrine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>From the date of this Agreement until the earlier of the Closing Date and the termination of this Agreement, Buyer and Seller
shall promptly advise the other Party in writing of (i) the occurrence, or failure to occur, of any event which could reasonably
be expected to cause any representation or warranty made by such Party contained in this Agreement to become untrue or incorrect
or (ii) the failure of such Party to comply with or perform in any material respect any covenants, agreements or obligations required
to be complied with or performed by such Party under this Agreement, in any such case to the extent such Party or its officers
and directors have actual knowledge of any such failure, occurrence or event. For the avoidance of doubt, no disclosure pursuant
to this <U>Section 5.4</U> shall be deemed to cure any breach of any representation, warranty, covenant, agreement or obligation
or affect any determination as to whether any of the conditions set forth in <U>Article VI</U> have been satisfied.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Subject to <U>Section 5.4(a)</U>, from the date of this Agreement until the earlier of the Closing Date and the termination
of this Agreement, Buyer and Seller shall reasonably cooperate and make such arrangements as are necessary to ensure that all applicable
safety data relating to the Business will transfer to Buyer upon the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 5.5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Confidentiality</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each of Buyer and Seller acknowledges that the information provided to them in connection with this Agreement and the consummation
of the Contemplated Transactions is subject to the terms of the Confidentiality Agreement. Effective upon, and only upon, the Closing,
the Confidentiality Agreement shall terminate with respect to information included in or related to the Business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>From and after the Closing, Seller will, and will cause its Affiliates and its and their Representatives, to keep confidential,
not disclose to any Person and not use any non-public, confidential or proprietary information in its possession, under its Control
or to which it has access relating to the Business; <U>provided</U> that Seller, its Affiliates and its and their Representatives
may use any such information constituting an Excluded Asset in connection with business activities not constituting the Business.
The obligations of Seller under this <U>Section 5.5(b)</U> shall not apply to information to the extent such information (A) becomes
generally available to the public without breach of Seller&rsquo;s obligations under <U>Section 5.1</U> or this <U>Section 5.5(b)</U>
or (B) is required to be disclosed by Law or any Order; <U>provided</U>, <U>however</U>, that in the case of the foregoing clause
(B), to the extent not prohibited by such Law or Order, Seller shall notify Buyer as early in advance of such disclosure as is
practicable to allow Buyer to take appropriate measures (and Seller shall reasonably cooperate, at the expense of Buyer, in the
taking of such measures) to preserve the confidentiality of such information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 5.6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Non-Competition; Right of First Negotiation</U>.</P>

<!-- Field: Page; Sequence: 46; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Non-Competition</U>. Seller agrees that, from the Closing Date to the date that is five years following the Closing (the
&ldquo;<U>Restricted Period</U>&rdquo;), none of Seller or any of its Affiliates (now existing or hereafter incorporated, formed
or otherwise organized) shall, alone or in conjunction with others, directly or indirectly, seek to Exploit, conduct clinical studies
with respect to, develop, manufacture or commercialize any product containing or comprising a monoclonal antibody that targets
human Interleukin 1 alpha.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Seller Right to Develop New Antibody</U>. Notwithstanding anything to the contrary herein, the restrictions set forth
in <U>Section 5.6(a)</U> shall not apply to the development of any monoclonal antibody that targets Interleukin 1 alpha that satisfies
all of the following characteristics (any such monoclonal antibody, a &ldquo;<U>New Antibody</U>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>such New Antibody is identified and developed as a result of a <I>de novo</I> discovery, which includes <B>[*****]</B> and
those developed in the future by Seller or any of its Affiliates without the use of or reference to <B>[*****]</B>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 1in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>such New Antibody qualifies as a new molecular entity under FDA regulations and guidelines; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>[*****]</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Additional Seller and Buyer Obligations</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Notwithstanding anything to the contrary set forth in <U>Section 5.6(b)</U>, Seller shall not, and shall cause each of its
Affiliates not to, directly or through any Third Party, develop, seek to Exploit, conduct clinical studies with respect to, manufacture
or commercialize any product containing or comprising a New Antibody for use in a Specified Indication; <U>provided</U> that the
restriction in this <U>Section 5.6(c)(i)</U> shall not apply with respect to any indication that becomes a Specified Indication
after a product containing or comprising a New Antibody has received the Required Commercialization Authorizations with respect
to such indication in (A) the <B>[*****]</B> or (B) <B>[*****]</B> of the <B>[*****]</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Seller shall, and shall cause its Affiliates to, grant Buyer exclusive rights in Dermatology to any Seller Patents covering
a New Antibody until the date that is five (5) years after the Closing Date solely for purposes of ensuring that any third-party
product containing such New Antibody will not be manufactured or commercialized for use in a Dermatology indication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[*****] Text omitted for confidential treatment. The redacted
information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 47; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Notwithstanding anything to the contrary set forth in <U>Section 5.6(b)</U>, (A) until <B>[*****]</B> Seller shall not,
and shall cause each of its Affiliates not to, file any IND with respect to a New Antibody, (B) until <B>[*****]</B> Buyer shall
not, and shall cause each of its Affiliates (and their respective licensees) not to, <B>[*****]</B> and (C) until <B>[*****]</B>
Buyer shall not, and shall cause each of its Affiliates (and their respective licensees) not to, <B>[*****]</B> (it being understood
that clauses (B) and (C) shall not prevent Buyer from undertaking any <B>[*****]</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Seller shall not, and shall cause its Affiliates not to, market, detail or promote any product containing or comprising
a New Antibody to dermatologists for any indication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Seller shall deliver to Buyer (A) on the first day of each calendar year during the Restricted Period, a written certification
from an authorized executive officer of Seller certifying Seller&rsquo;s and its Affiliates&rsquo; compliance with the provisions
of this <U>Section 5.6</U> and (B) following the designation of a New Antibody as a lead candidate by Seller and the availability
of sufficient binding and sequencing data in respect of such New Antibody, but prior to the commencement of any clinical trials
for such New Antibody, a written certification from a confidential Third Party auditor mutually acceptable to Buyer and Seller
(which audit shall be at Seller&rsquo;s sole expense) certifying that any New Antibody in respect of which Seller or any of its
Affiliates has filed an IND was identified and developed in compliance with <U>Section 5.6(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In the event that any Third Party (including any licensee) acquires rights to a New Antibody or New Antibody Products, Seller
shall cause such Third Party to be bound by the requirements of <U>Sections 5.6(c)(i)</U>, <U>5.6(c)(ii)</U>, <U>5.6(c)(iii)</U>
and <U>5.6(c)(iv)</U> and <U>5.6(c)(v)(A)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(vii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In the event that any Third Party (including any licensee) acquires rights to the Compound, Buyer shall cause such Third
Party to be bound by the requirements of <U>Section 5.6(c)(iii)(B)</U> and <U>Section 5.6(c)(iii)(C)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[*****] Text omitted for confidential treatment. The redacted
information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 48; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Buyer Right of First Negotiation</U>. If Seller or any of its Affiliates commences development of a New Antibody during
the Restricted Period, Seller and its Affiliates shall not be permitted to sell, license or otherwise transfer control of (including
pursuant to a transfer of control of Seller), or commence or participate in negotiations to, or enter into any agreement to, sell,
license or otherwise transfer control of (including pursuant to a transfer of control of Seller), any rights to Exploit such New
Antibody (the &ldquo;<U>Restricted Actions</U>&rdquo;), including any rights in respect of the development or commercialization
of any pharmaceutical product containing such New Antibody (any such product, including all dosage forms, presentations, formulations
and line extensions thereof, a &ldquo;<U>New Antibody Product</U>&rdquo;), to any Third Party (including any rights to partner
with Seller or any of its Affiliates) unless Seller first provides Buyer with a right of first negotiation on the following terms
and conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If Seller or any of its Affiliates determines to seek to sell, license or otherwise transfer control (including pursuant
to a transfer of control of Seller) of any rights to Exploit such New Antibody, including any rights in respect of the development
or commercialization of any New Antibody Product, or receives any <I>bona fide</I> offer in respect of such New Antibody, any New
Antibody Product or control of Seller (any potential counterparty to such transactions, a &ldquo;<U>Counterparty</U>&rdquo;), Seller
shall provide Buyer with written notice of such determination or such offer (an &ldquo;<U>Offer Notice</U>&rdquo;), which such
Offer Notice shall (A) state whether such determination or offer is in respect of such New Antibody or in respect of one or more
specific New Antibody Products (and shall identify such New Antibody or New Antibody Products, as applicable) and (B) in the case
of a <I>bona fide</I> offer in respect of such New Antibody or New Antibody Product or control of Seller, shall provide reasonable
detail regarding such offer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Within <B>[*****]</B> days of receipt of any Offer Notice <B>[*****]</B> (the &ldquo;<U>Offer Period</U>&rdquo;), Buyer
may deliver to Seller a non-binding, good faith written notice expressing Buyer&rsquo;s desire to negotiate in respect of such
New Antibody, such New Antibody Products or control of Seller, as applicable (a &ldquo;<U>Negotiation Notice</U>&rdquo;). If Buyer
delivers such Negotiation Notice within the Offer Period, Buyer and Seller shall negotiate in good faith, for <B>[*****]</B> days
after the delivery of such Negotiation Notice <B>[*****]</B> (the &ldquo;<U>Negotiation Period</U>&rdquo;), the terms of an agreement
under which Buyer would acquire rights to such New Antibody or such New Antibody Products or to acquire control of Seller.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[*****] Text omitted for confidential treatment. The redacted
information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 49; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If (A) Buyer does not provide Seller with a Negotiation Notice within the Offer Period or (B) Buyer does provide Seller
with such Negotiation Notice within the Offer Period, but the Parties are unable to, after good faith negotiation, reach agreement
during the Negotiation Period, then Seller may take any of the Restricted Actions in respect of such New Antibody, such New Antibody
Products or control of Seller; <U>provided</U>, that, if Seller delivers an Offer Notice which states that such Offer Notice is
in respect of one or more specific New Antibody Products, Seller shall not be permitted to take any of the Restricted Actions with
respect to rights that are not exclusively related to such New Antibody Products without first delivering a new Offer Notice covering
such other rights and providing for a new Offer Period and, upon delivery of a Negotiation Notice, a new Negotiation Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>During any Offer Period and/or Negotiation Period, Seller will, and will cause its Affiliates to, reasonably cooperate with
Buyer and its Representatives to facilitate Buyer&rsquo;s diligence of such New Antibody or New Antibody Product (or of Seller
itself, as applicable), including by (A) furnishing to Buyer and its Representatives all information concerning such New Antibody
or New Antibody Product or the assets, properties, operations and businesses of Seller, as applicable, as Buyer or its Representatives
may reasonably request and (B) substantially concurrently with the delivery of the Offer Notice, and thereafter on a reasonably
current basis, furnishing to Buyer and its Representatives all diligence materials that are provided to a Counterparty, subject,
in each case, to Buyer and its Representatives entering into customary agreements or other arrangements with respect to the confidentiality
of any such diligence materials or other information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(v)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If within <B>[*****]</B> days of the expiration of the Negotiation Period Seller does not enter into a definitive agreement
with a Third Party pursuant to which such Third Party agrees to acquire rights to the New Antibody or New Antibody Products or
control of Seller that, in each case was the subject of the applicable Offer Notice, Seller shall again comply with the requirements
of this <U>Section 5.6(d)</U> prior to taking any of the Restricted Actions in respect of such New Antibody or such New Antibody
Products or a transfer of control of Seller.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(vi)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Notwithstanding anything to the contrary set forth herein, this <U>Section 5.6(d)</U> shall not apply to the entry by Seller
or its Affiliates into any subcontract or similar agreement with a Third Party to subcontract to such Third Party the research
or development of a New Antibody or New Antibody Product, so long as Seller or its Affiliates retains the exclusive right to commercialize
the New Antibody or the New Antibody Product (and the exclusive right to the economic benefits thereof).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[*****] Text omitted for confidential treatment. The redacted
information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 50; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Acknowledgments, Interpretation and Validity</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Seller agrees and acknowledges that the covenants in this <U>Section 5.6</U> are reasonable and valid in all respects (including
with respect to the subject matter, Restricted Period, and geographical area described in <U>Section 5.6(a)</U>) and are necessary
to protect the interests of Buyer in the Business and in the confidential information acquired by Buyer, and such covenants represent
only a limited restraint. Further, Seller acknowledges that, without the restrictions contained in this <U>Section 5.6</U>, the
benefits of the Contemplated Transactions could be devalued, lost or circumvented, particularly in light of the nature of the Business
and the ongoing development of the Compound, and that Buyer would not have entered into this Agreement without the restrictions
contained in this <U>Section&nbsp;5.6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Seller acknowledges and agrees that the provisions of this <U>Section&nbsp;5.6</U> are necessary and reasonable to protect
Buyer in the conduct of its business and are a material inducement to Buyer&rsquo;s execution and delivery of this Agreement and
its willingness to enter into the Contemplated Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>It is the desire and intent of the Parties that this <U>Section&nbsp;5.6</U> will be enforced to the fullest extent permissible
under the Laws applied in each jurisdiction in which enforcement is sought. If any restriction set forth in this <U>Section&nbsp;5.6</U>
is found by any court of competent jurisdiction to be unenforceable for any reason (<I>e.g.</I>, because it extends for too long
a period of time, over too great a range of activities or in too broad a geographic area), this <U>Section&nbsp;5.6</U> shall be
interpreted to extend over the maximum period of time, range of activities or geographic area as to which it may be enforceable.
The agreements contained in this <U>Section&nbsp;5.6 </U>shall each constitute a separate agreement independently supported by
good and adequate consideration. For the avoidance of doubt, the Parties hereby acknowledge that Seller will benefit substantially
from the consummation of the Contemplated Transactions and that the consideration that Seller will receive upon such consummation
is adequate to support Seller&rsquo;s agreement to be bound by the covenants set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Remedies</U>. In accordance with <U>Section 9.8(c)</U>, Buyer will be entitled to injunctive or other equitable relief
to enforce the provisions hereof, in addition to such other remedies to which Buyer may be entitled, including the recovery of
money damages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Extensions of Limitations</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If Seller or any of its Affiliates violates any term or provision of this <U>Section&nbsp;5.6</U>, the duration set forth
in <U>Section&nbsp;5.6(a)</U> shall automatically be extended as against Seller and its subsidiaries for a period equal to the
periods during which Seller or such subsidiary shall have been in violation of this <U>Section&nbsp;5.6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If Seller or any of its Affiliates fails to comply with Buyer&rsquo;s due diligence requests pursuant to <U>Section 5.6(d)(iv)</U>
above reasonably promptly following the request therefor, the Offer Period or Negotiation Period, as applicable, shall automatically
be extended by a number of days equal to the delay by Seller or any of its Affiliates in providing the requested materials.</P>

<!-- Field: Page; Sequence: 51; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 5.7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Other Agreements</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>From the date hereof until the Closing Date, Buyer and Seller shall use commercially reasonable efforts to negotiate in
good faith and enter into a Quality Assurance Agreement, in form and substance reasonably acceptable to each of Buyer and Seller
(the &ldquo;<U>Quality Assurance Agreement</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If the Parties determine that a pharmacovigilance agreement is necessary, Buyer and Seller shall use commercially reasonable
efforts to negotiate in good faith and enter into such a pharmacovigilance agreement, in form and substance reasonably acceptable
to each of Buyer and Seller, as promptly as reasonably practicable following such determination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>On and after the Closing Date, Seller shall not, and shall cause its Affiliates not to, (i) incur, create, assume or permit
the incurrence, creation or assumption of any Lien (other than Permitted Liens) with respect to any Inventory or (ii) use, transfer,
sell, assign or otherwise dispose of any Inventory, other than, in the case of this clause (ii), in accordance with the terms of
the Clinical Manufacturing Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>As promptly as practicable (and in any event, no later than 30 days) following the date hereof, Seller shall provide Buyer
with true, accurate and complete copies of all Contracts (i) to which Seller or any of its Affiliates is a party or by which Seller
or any of its Affiliates is bound, in either case, that are related to the Business or (ii) to which any of the Purchased Assets
are subject, in each of cases (i) and (ii) that are not Assumed Contracts or Excluded Contracts (the &ldquo;<U>Reviewable Contracts</U>&rdquo;).
From the date hereof until the date that is six months following the Closing Date, if Buyer determines in good faith that any of
the Reviewable Contracts are primarily related to or material to the Business or are reasonably necessary to conduct the Business,
Buyer may designate such Reviewable Contracts as Assumed Contracts by delivering written notice to Seller of such designation and,
upon delivery of such notice, such Reviewable Contracts shall be deemed to be Assumed Contracts for all purposes hereunder. If
delivery of any such notice is made on or after the Closing Date, the Reviewable Contracts designated in such notice shall be deemed,
subject to <U>Section 2.6</U>, to have been assigned or transferred under this Agreement as of the date of delivery of such notice
(it being understood that the date of the assignment or transfer, taking into account the operation of <U>Section 2.6</U>, if applicable,
shall be deemed the &ldquo;Transfer Date&rdquo; with respect to such Reviewable Contracts).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 52; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 5.8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Certain Tax Matters</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Transfer Taxes</U>. All recordation, transfer, documentary, excise, sales, value added, use, stamp, conveyance or other
similar Taxes, duties or governmental charges, and all recording or filing fees or similar costs, imposed or levied by reason of,
in connection with or attributable to this Agreement, the Related Documents or the Contemplated Transactions (collectively, &ldquo;<U>Transfer
Taxes</U>&rdquo;) shall be the borne solely by Buyer; <U>provided</U>, that any Transfer Taxes that are not recoverable by Buyer
shall be borne <B>[*****]</B>. Seller (or an Affiliate of Seller) shall prepare, or cause to be prepared, all Tax Returns required
to be filed in connection with such Transfer Taxes, and Buyer shall provide any information that is reasonably requested by Seller
in connection with the preparation of such Tax Returns. Buyer and Seller shall reasonably cooperate in providing such certificates
or other documentation as may be necessary or advisable to avoid the collection and payment of Transfer Taxes that would otherwise
be due and payable absent the provision of such documentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Allocation of Taxes</U>. In the case of a taxable period that includes, but does not end on, the Closing Date (a &ldquo;<U>Straddle
Period</U>&rdquo;), (a)&nbsp;Taxes imposed on a periodic basis (such as real, personal and intangible property taxes) for the Pre-Closing
Tax Period shall be equal to the amount of such Taxes for the entire Straddle Period multiplied by a fraction, the numerator of
which is the number of days during the Straddle Period that are in the Pre-Closing Tax Period and the denominator of which is the
number of days in the Straddle Period; and (b)&nbsp;Taxes (other than Taxes described in clause (a)) for any Pre-Closing Tax Period
shall be computed as if such taxable period ended as of the close of business on the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Withholding</U>. Notwithstanding anything in this Agreement to the contrary, Buyer and its Affiliates shall be entitled
to deduct and withhold from any amount payable pursuant to this Agreement such amounts as Buyer believes in good faith are required
to be deducted and withheld with respect to the making of such payment under any provision of federal, state or local (in each
case, whether domestic or foreign) Tax Law and pay such amounts over to the appropriate Taxing Authority. If Buyer determines that
an amount is so required to be deducted and withheld on its payment of the Purchase Price, Buyer shall use commercially reasonable
efforts to provide to Seller, at least three days prior to the expected Closing Date, written notice of its intent to deduct and
withhold on such payment, which notice shall include a reasonably detailed calculation of the amount to be deducted and withheld
and the applicable provision of federal, state, local or non-U.S. Tax Law pursuant to which such deduction and withholding is required.
Upon delivery of such notice, Buyer shall allow Seller a reasonable opportunity to provide, prior to the expected Closing Date,
such forms or other evidence that would reduce or eliminate the amounts required to be deducted and withheld from such payment.
To the extent that amounts are deducted and withheld and paid over to the appropriate Taxing Authority pursuant to this <U>Section
5.8(c)</U>, such amounts shall be treated for all purposes of this Agreement as having been paid to the party in respect of which
such deduction and withholding was made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[*****] Text omitted for confidential treatment. The redacted
information has been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 53; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Cooperation and Exchange of Information</U>. Each of Seller and Buyer shall, and shall cause their respective Affiliates
to, (i) provide the other with such assistance as may reasonably be requested by the other Party in connection with the preparation
of any Tax Return, audit or other examination by any Taxing Authority or Action relating to liability for Taxes in connection with
the Purchased Assets, (ii) retain and provide the other with any records or other information that may be relevant to such Tax
Return, audit or examination, Action or determination and (iii) provide the other with any final determination of any such audit
or examination, Action or determination that affects any amount required to be shown on any Tax Return of the other for any period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Tax Treatment of Payments</U>. Except to the extent otherwise required by Law, Seller and Buyer shall, and shall cause
their Affiliates to, treat any payment under <U>Section 2.5</U> and <U>Article VII</U> as an adjustment to the Purchase Price for
Tax purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 5.9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Public Announcements</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Neither Buyer nor Seller, nor any Affiliate of either Party, shall issue any press release or otherwise make any public
statement with respect to the provisions of this Agreement or the Contemplated Transactions without the prior written consent of
the other Party. Notwithstanding anything to the contrary in this Agreement or any Related Document, either Party may issue a press
release or make a public statement with respect to the Contemplated Transactions without the consent of the other Party as may
be required by Law or the rules and regulations of any applicable securities exchange or market. If any Party proposes to issue
a press release or make a public statement with respect to the Contemplated Transactions pursuant to this <U>Section&nbsp;5.9</U>,
it will provide copies of such press release or public statement to the other Party before such press release or public statement
is made, unless this would be in breach of any Law or the rules and regulations of any applicable securities exchange or market,
in which case a copy of such press release or public statement will be provided to the other Party as soon as reasonably practicable
or in accordance with such Law, rules or regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>From and after the Closing, except as required by Law or the rules and regulations of any applicable securities exchange
or market, neither Seller nor any of its Affiliates shall issue any press release or otherwise make any public statement with respect
to the Business, other than with respect to Patents licensed to Seller for indications excluding Specified Indications, without
the consent of Buyer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 5.10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Employee Matters</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Offers of Employment</U>. Seller shall deliver to Buyer a final, true, accurate and complete version of <U>Schedule 3.10(h)</U>
no later than 15 Business Days prior to the Closing and, no later than five Business Days prior to the Closing, Buyer or one of
its Affiliates shall offer employment commencing as of immediately following the Closing to each active Business Employee on terms
and conditions consistent with this <U>Section 5.10</U>; <U>provided</U> that, in the event any individual is identified as a Business
Employee in accordance with this Agreement less than 15 Business Days prior to the Closing, such offer shall be made within 10
Business Days of Seller delivering updated <U>Schedules 1.1(a)</U> and <U>3.10(h)</U> to Buyer that include such individual. Any
such offers made pursuant to this <U>Section 5.10</U> shall be contingent on the Business Employee&rsquo;s satisfaction of Buyer&rsquo;s
typical employment screening processes. Seller and its Affiliates shall encourage the Business Employees to accept the offers of
employment pursuant to this <U>Section 5.10</U>. Each Business Employee who accepts an offer of employment pursuant to this <U>Section
5.10</U> and becomes employed by Buyer or one of its Affiliates pursuant to this <U>Section 5.10</U> shall be referred to herein
as a &ldquo;<U>Transferred Business Employee</U>.&rdquo; In the case of any individual who becomes a Transferred Business Employee
following the Closing Date, all references in this Agreement (i) to the Closing Date (including in <U>Section 5.1</U>) shall be
deemed to be references to the date that such individual becomes a Transferred Business Employee and (ii) to the Transfer Time
shall be deemed to be references to 12:01 a.m., local time, on the date that such individual becomes a Transferred Business Employee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 54; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Comparability</U>. For a period of not less than 12 months following the applicable Transfer Time, each Transferred Business
Employee shall receive during their continued employment with Buyer and its Affiliates: (i) at least the same base salary or wage
rate and annual cash incentive opportunities as those provided to such Transferred Business Employee immediately prior to the Transfer
Time; and (ii) other compensation and employee benefits that are substantially comparable in the aggregate to either, at Buyer&rsquo;s
election, (A) the other compensation and employee benefits (excluding any equity-based compensation, defined benefit pension or
post-employment health or welfare benefits, and retention, change in control or other similar payments or benefits) provided to
such Transferred Business Employee immediately prior to the Transfer Time, or (B) the other compensation and employee benefits
provided to similarly situated new hires of Buyer&rsquo;s ultimate parent entity (&ldquo;<U>Parent</U>&rdquo;) and its Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Service Credit</U>. Effective immediately after the applicable Transfer Time and thereafter, Buyer shall provide, or
shall cause its Affiliates to provide, that periods of employment with Seller (including any current or former Affiliate of Seller
or any predecessor of Seller) shall be taken into account (i) for purposes of vesting (but not eligibility or benefit accrual)
under Parent&rsquo;s defined benefit pension plan, (ii) for purposes of eligibility and benefit accrual for vacation under Parent&rsquo;s
vacation program, (iii) for purposes of eligibility to participate in any health or welfare plan maintained by Parent (other than
any post-employment health or post-employment welfare plan) and Parent&rsquo;s 401(k) plan, and (iv) for benefit accrual purposes
under Parent&rsquo;s severance plan (in the case of each of clauses (i), (ii), (iii) and (iv), solely to the extent that (A) such
periods of employment are taken into account under analogous Business Employee Benefit Plans before the applicable Transfer Time,
to the extent applicable, and (B) Parent makes such plan or program available to Transferred Business Employees, and not in any
case where credit would result in duplication of benefits).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Welfare Benefits</U>. With respect to any welfare plan maintained by Parent or any of its Affiliates in which a Transferred
Business Employee is eligible to participate after the Transfer Time, Parent shall, and shall cause its Affiliates to, (i)&nbsp;waive
all limitations as to preexisting conditions and exclusions with respect to participation and coverage requirements applicable
to such employee to the extent such conditions and exclusions were satisfied or did not apply to such employee under the welfare
plans of Seller and its Affiliates prior to the applicable Transfer Time and (ii)&nbsp;provide each Transferred Business Employee
with credit for any co-payments and deductibles paid prior to the applicable Transfer Time, for the calendar year in which such
Transfer Time occurs, in satisfying any analogous deductible or out-of-pocket requirements to the extent applicable under any such
plan. For the avoidance of doubt, neither Parent nor any of its Affiliates shall be required to take any action to the extent Parent
determines that such action could make a Transferred Business Employee (or eligible dependent) ineligible for a benefit (for example,
if credit for past contributions would make the Transferred Business Employee ineligible for health savings account contributions
from Parent).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 55; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Accrued Amounts</U>. As soon as practicable following the Transfer Time, Seller shall pay all earned but unpaid amounts
due to any Transferred Business Employee and shall compensate each Transferred Business Employee for all vacation and other paid
time off that have accrued and not been used or paid prior to the applicable Transfer Time. Buyer and its Affiliates will cooperate
in good faith with any Transferred Business Employees with respect to any vacation commitments communicated by such Transferred
Business Employees to Seller in accordance with Seller&rsquo;s standard operating procedures and/or vacation policies prior to
the applicable Transfer Time in respect of periods occurring subsequent to the Transfer Time; it being understood that any such
vacation commitments ultimately honored by Buyer and its Affiliates shall count against the applicable Transferred Business Employee&rsquo;s
paid-time-off accrued during his or her service with Buyer and its Affiliates, or shall be unpaid.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Employees on Leave</U>. With respect to any Business Employee who, as of the Closing Date, is on approved leave of absence
from work with Seller and its Affiliates and is expected to return to active employment, Buyer or its applicable Affiliate shall
offer employment to such individual on the earliest practicable date following the return of such individual to active employment
with Seller and its Affiliates and otherwise on terms and conditions consistent with this <U>Section 5.10</U>; <U>provided</U>
that such employee returns to active employment within 180 days following the Closing Date or such later time as required by applicable
Law. Seller shall promptly notify Buyer of the occurrence and end of any such leave of absence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Seller Long-Term Incentive Awards</U>. Outstanding Seller long-term incentive awards held by any Transferred Business
Employee as of the applicable Transfer Time shall be treated as set forth on <U>Schedule 5.10(g)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Third-Party Beneficiaries</U>. The Parties acknowledge and agree that all provisions contained in this <U>Section&nbsp;5.10</U>
are included for the sole benefit of the Parties. This Agreement is not intended by the Parties to, and nothing in this <U>Section&nbsp;5.10</U>
or otherwise in this Agreement, whether express or implied, shall, (i) constitute an amendment to any Business Employee Benefit
Plan or any other employee benefit plan, program, policy, agreement or arrangement, (ii) create any obligation of the Parties to
any person (other than the other Parties) with respect to any employee compensation or benefit plan, program, policy, agreement
or arrangement of the Parent or Seller or any of their respective Affiliates or (iii) confer on any Business Employee or any other
person (other than the Parties) any rights or remedies (including third-party beneficiary rights).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 5.11.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Regulatory Matters</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Transfer of Seller Regulatory Authorizations</U>. Seller will, and will cause its Affiliates to, assist with the transfer
of the Seller Regulatory Authorizations to Buyer and, as may be reasonably requested by Buyer, in Buyer&rsquo;s preparation of
all notifications or filings required to be filed with the applicable Governmental Authority in order to transfer the Seller Regulatory
Authorizations to Buyer. Without limiting the foregoing and to the extent applicable with respect to any particular Seller Regulatory
Authorizations, (i) Seller shall, and shall cause its Affiliates to, submit or file all documents required to be submitted by Seller
or such Affiliates, as the current owner of a Regulatory Authorizations, pursuant to 21 C.F.R. part 314.72; (ii) Buyer shall submit
or file all documents required to be submitted by Buyer, as the new owner of a Regulatory Application, pursuant to 21 C.F.R. part
314.72; (iii) Seller shall, and shall cause its Affiliates to, take all other actions imposed upon a current owner of a Regulatory
Application, by applicable Law or Governmental Authority, to transfer the Seller Regulatory Authorizations to Buyer; and (iv) Buyer
shall take all other actions imposed upon a new owner of a Regulatory Application, as may be required, by applicable Law or the
applicable Governmental Authority, to accept the transfer of the Seller Regulatory Authorizations and responsibility therefor from
Seller. Seller and Buyer each agree to submit, and to cause each of their respective Affiliates to submit, all notifications or
filings it is required to submit pursuant to the foregoing requirements of this <U>Section 5.11(a)</U> within the <B>[*****]</B>
days period immediately following the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify">[*****] Text omitted for confidential treatment. The redacted information has
been excluded because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 56; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Buyer Responsibilities</U>. From and after the Closing Date, Buyer (on behalf of Seller or its Affiliate to the extent
required under applicable Law), at its cost, shall be solely responsible (subject to Seller&rsquo;s obligations set forth in clause
(c) below) and liable for (i) taking all actions, paying all fees and conducting all communication with the appropriate Governmental
Authority required by Law in respect of the Seller Regulatory Authorizations, including preparing and filing all reports (including
adverse drug experience reports) with the appropriate Governmental Authority; (ii) investigating all complaints and reports of
adverse drug experiences with respect to the Compound pursuant to such Seller Regulatory Authorizations (whether Exploited before
or after transfer of such Seller Regulatory Authorizations); and (iii) fulfilling all other applicable legal and regulatory obligations
of a holder of each Seller Regulatory Authorization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Complaints</U>. After the Closing Date, Seller shall notify Buyer promptly (and in any event within the time period required
by Law) if Seller or any of its Affiliates receives a complaint or a report of an adverse drug experience with respect to the Compound.
In addition, during the 18-month period immediately following the Closing Date, Seller shall, and shall cause its Affiliates to,
use commercially reasonable efforts to assist Buyer (and Buyer shall reimburse Seller its reasonable expenses incurred in connection
therewith) in connection with the investigation of and response to any complaint or adverse drug experience report related to the
Compound. All notifications pursuant to this <U>Section&nbsp;5.11(c)</U> shall be by electronic mail at such addresses agreed upon
by the Parties&rsquo; respective safety divisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Cooperation</U>. Seller shall, and shall cause its Affiliates to, use commercially reasonable efforts to cooperate with
Buyer in supplying reasonable information or assistance in Buyer&rsquo;s fulfillment of its obligations under this <U>Section 5.11</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 57; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 5.12.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Trade Secrets; Patents; Trademarks</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Seller shall, and shall cause its Affiliates and its and their Representatives to, provide or cause to be provided to Buyer
(subject to Seller&rsquo;s retained rights pursuant to the terms of the IP License Agreement) all Trade Secrets included within
the Seller Intellectual Property promptly following the Closing (and in any event within 10 Business Days of the Closing Date)
and Seller shall, and shall cause its Affiliates and its and their Representatives to, maintain the Trade Secret status of all
such Trade Secrets from and after the date of this Agreement in accordance with <U>Section&nbsp;5.5</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Seller agrees that at no time through expiration of the Patents included within the Seller Intellectual Property shall it
of any of its Affiliates challenge or oppose, or commence any Action challenging or opposing, directly or indirectly or assist
any other Person in challenging or opposing directly or indirectly the validity and/or enforceability of any rights of Buyer or
any of its Affiliates in such Patents at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Seller agrees that Buyer and its Affiliates shall be entitled to use Seller&rsquo;s TRUE HUMAN trademark in regulatory filings,
patent applications and other documents when describing or referencing the development process for the Compound.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Seller acknowledges and agrees that the Patents listed on <U>Schedule 5.12(d)</U>, and any Patents claiming priority to
the Patents listed on <U>Schedule 5.12(d)</U>, do not and will not include any claims reciting the Compound or relating directly
to the Compound or any anti-Interleukin 1 alpha antibody, and lack the disclosure required to support any such claims.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 5.13.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Expenses</U>. Except as expressly set forth herein, each of Seller and Buyer shall bear its own costs and expenses incurred
in connection with this Agreement and the Contemplated Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 5.14.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Further Assurances</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Seller shall, and shall cause its Affiliates to, at any time and from time to time after the Closing Date, upon the request
of Buyer, do, execute, acknowledge, deliver and file, or cause to be done, executed, acknowledged, delivered or filed, all such
further acts, deeds, transfers, conveyances, assignments or assurances as may be reasonably required for the better transferring,
conveying, assigning and assuring to Buyer, or for the aiding and assisting in the reducing to possession by Buyer of, any of the
Purchased Assets, or for otherwise carrying out the purposes of this Agreement and the Related Documents and the consummation of
the Contemplated Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Subject to, and without altering the rights and obligations set forth in, <U>Section 2.6</U>, for a period of 18 months
from and after the Closing Date, if either Buyer or Seller becomes aware that any of the Purchased Assets have not been transferred
to Buyer or that any of the Excluded Assets have been transferred to Buyer, it shall promptly notify the other and the Parties
hereto shall, as promptly as reasonably practicable, use commercially reasonable efforts, at Seller&rsquo;s sole cost and expense,
to ensure such assets are transferred to the correct owner, with any necessary Third Party consents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 58; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 5.15.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Access</U>. From and after the Closing Date for a period of three years, Seller shall provide Buyer with reasonable access,
upon reasonable written notice and during normal business hours, to the management and other personnel of Seller for the purpose
of (i) discussing all reasonable inquiries regarding the Purchased Assets or the Compound Program and (ii) providing such other
assistance as Buyer may reasonably request related to the Purchased Assets or the Compound Program or the sale, conveyance, delivery,
transfer and assignment thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-variant: small-caps"><B>ARTICLE
VI</B></FONT><BR>
<BR>
<B>Conditions Precedent</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 6.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Conditions to Each Party&rsquo;s Obligations</U>. The respective obligations of each party to effect the Closing are
subject to the satisfaction or waiver on or prior to the Closing Date of the following conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Governmental Approvals</U>. Any authorizations, consents, Orders or approvals of, or declarations or filings with, or
expirations of waiting periods imposed by, any Governmental Authority under any applicable Law that are required to effect the
Closing shall have been made, obtained or terminated or shall have expired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Injunctions or Restraints</U>. No temporary restraining order, preliminary or permanent injunction or other Order
issued by any court of competent jurisdiction or other Law (collectively, &ldquo;<U>Legal Restraints</U>&rdquo;) which has the
effect of restraining, enjoining or otherwise preventing the consummation of the Contemplated Transactions shall be in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 6.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Conditions to Obligations of Buyer</U>. The obligation of Buyer to effect the Closing is subject to the satisfaction
or waiver by Buyer on or prior to the Closing Date of the following additional conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Representations and Warranties</U>. The representations of warranties of Seller contained in this Agreement that are
qualified as to materiality or Material Adverse Effect shall be true and correct, and the representations and warranties of Seller
contained in this Agreement that are not so qualified shall be true and correct in all material respects, in each case as of the
date of this Agreement and as of the Closing Date as though made at such time, except to the extent such representations and warranties
expressly relate to an earlier date, in which case as of such earlier date. Buyer shall have received a certificate signed on behalf
of Seller by an authorized executive officer of Seller to such effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Performance of Obligations of Seller</U>. Seller shall have performed and complied in all material respects with all
of its covenants, agreements and obligations contained in this Agreement and required to be performed or complied with on or prior
to the Closing Date. Buyer shall have received a certificate signed on behalf of Seller by an authorized executive officer of Seller
to such effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Material Adverse Effect</U>. Since the date of this Agreement, there shall not have occurred a Material Adverse Effect.
Buyer shall have received a certificate signed on behalf of Seller by an authorized executive officer of Seller to such effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 59; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>No Actions</U>. There shall not be pending or threatened any Action brought by any Governmental Authority or any other
Person having a reasonable likelihood of prevailing challenging or seeking to restrain or prohibit the consummation of the Contemplated
Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 6.3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Conditions to Obligations of Seller</U>. The obligation of Seller to effect the Closing is subject to the satisfaction
or waiver by Seller on or prior to the Closing Date of the following additional conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Representations and Warranties</U>. The representations of warranties of Buyer contained in this Agreement that are qualified
as to materiality or Material Adverse Effect shall be true and correct, and the representations and warranties of Buyer contained
in this Agreement that are not so qualified shall be true and correct in all material respects, in each case as of the date of
this Agreement and as of the Closing Date as though made at such time, except to the extent such representations and warranties
expressly relate to an earlier date, in which case as of such earlier date. Seller shall have received a certificate signed on
behalf of Buyer by an authorized executive officer of Buyer to such effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Performance of Obligations of Seller</U>. Buyer shall have performed and complied in all material respects with all of
its covenants, agreements and obligations contained in this Agreement and required to be performed or complied with on or prior
to the Closing Date. Seller shall have received a certificate signed on behalf of Buyer by an authorized executive officer of Buyer
to such effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 6.4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Frustration of Closing Conditions</U>. Neither Seller nor Buyer may rely on the failure of any condition set forth in
<U>Section 6.1</U>, <U>6.2</U> or <U>6.3</U>, as the case may be, to be satisfied if such failure was caused by such party&rsquo;s
failure to comply with the terms of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-variant: small-caps"><B>ARTICLE
VII</B></FONT><BR>
<BR>
<B>Indemnification</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 7.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Indemnification of Buyer</U>. (a) From and after the Closing, Seller shall indemnify Buyer and its Affiliates and each
of their respective officers, directors, employees, equity holders, agents and other Representatives (each, a &ldquo;<U>Buyer Indemnified
Party</U>&rdquo;) against and hold each Buyer Indemnified Party harmless from any and all debts, losses, Liabilities, damages,
Liens, Taxes, penalties, costs of investigation, other costs and expenses (whether known or unknown, absolute or contingent, liquidated
or unliquidated, direct or indirect, due or to become due, accrued or not accrued, asserted or unasserted or otherwise) (collectively,
&ldquo;<U>Losses</U>&rdquo;) suffered or incurred by such Buyer Indemnified Party, arising from, relating to or otherwise in connection
with:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any breach of any representation or warranty of Seller contained in this Agreement or any Related Document, without giving
effect to any materiality threshold or qualifier contained therein (including in the definition of Material Adverse Effect);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 60; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any breach of or failure to perform any covenant or agreement of Seller contained in this Agreement or any Related Document;
or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any Excluded Liability or Excluded Asset.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The consent of Seller shall not be required in order for Buyer to be indemnified under this <U>Article&nbsp;VII</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In the case of a Buyer Indemnified Party&rsquo;s rights to indemnification pursuant to this <U>Section 7.1</U>, for as long
as there are funds available in the Escrow Fund to cover the Buyer Indemnified Parties&rsquo; indemnifiable Losses, any and all
Losses payable by Seller to the Buyer Indemnified Parties with respect to such indemnifiable Losses will be paid in cash first
out of the Escrow Fund, and in the event such Losses exceed, or are not paid and satisfied in full from, the Escrow Fund, will
be paid directly by Seller to the applicable Buyer Indemnified Parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 7.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Indemnification of Seller Indemnified Parties</U>. (a) From and after the Closing, Buyer shall indemnify Seller and its
Affiliates and each of their respective officers, directors, employees, equity holders, agents and Representatives (each a &ldquo;<U>Seller
Indemnified Party</U>&rdquo;) against and hold each Seller Indemnified Party harmless from any and all Losses suffered or incurred
by any such Seller Indemnified Party arising from, relating to or otherwise in connection with:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any breach of any representation or warranty of Buyer contained in this Agreement or any Related Document, without giving
effect to any materiality threshold or qualifier contained therein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any breach of or failure to perform any covenant or agreement of Buyer contained in this Agreement or any Related Document;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any Assumed Liability; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(iv)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>any Liabilities arising out of Buyer&rsquo;s or its Affiliates&rsquo; operation of the Purchased Assets after the Closing,
excluding, for the avoidance of doubt, any Excluded Liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 7.3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Limitations</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Notwithstanding anything to the contrary contained herein, no Buyer Indemnified Party or Seller Indemnified Party, as applicable,
shall be entitled to be indemnified pursuant to <U>Section&nbsp;7.1(a)(i)</U> and <U>Section&nbsp;7.2(a)(i)</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>unless and until the aggregate of all Losses for which the Buyer Indemnified Parties or the Seller Indemnified Parties,
as applicable, would, but for this paragraph (i), be entitled to indemnification hereunder exceeds on a cumulative basis $5,000,000
(the &ldquo;<U>Indemnity Threshold</U>&rdquo;), at which point each Buyer Indemnified Party or Seller Indemnified Party, as applicable,
shall be entitled to be indemnified for the aggregate of all Losses in excess of the Indemnity Threshold; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 61; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>unless the amount of an individual claim for Losses under <U>Section&nbsp;7.1(a)(i)</U> or <U>Section&nbsp;7.2(a)(i)</U>
(aggregating all claims and Losses arising from substantially the same or similar facts as applicable to each of <U>Section 7.1(a)(i)</U>
or <U>Section&nbsp;7.2(a)(i)</U>), as applicable, exceeds $25,000, and no such claim shall be applied toward the Indemnity Threshold;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><U>provided</U>, <U>however</U>,
that the foregoing provisions of this <U>Section&nbsp;7.3(a)</U> shall not apply with respect to any act of fraud or (i) any breach
of or inaccuracy in the representations and warranties set forth in <U>Sections&nbsp;3.1</U>, <U>3.2(a)</U>, <U>3.4(a)</U>, <U>3.5(a)</U>,
<U>3.5(j)</U>, <U>3.9</U>, or <U>3.14</U> (the &ldquo;<U>Specified Representations</U>&rdquo;) or (ii) any breach of the representations
and warranties set forth in <U>Sections&nbsp;4.1</U>, <U>4.2(a)</U> or <U>4.5</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Other than in the case of any act of fraud (where the rights of Buyer Indemnified Parties or Seller Indemnified Parties,
as applicable, shall not be limited by anything set forth in this Agreement to the contrary), in no event shall the aggregate amount
for which Buyer Indemnified Parties or Seller Indemnified Parties, as applicable, shall be indemnified and held harmless under
<U>Section&nbsp;7.1(a)(i)</U> and <U>Section&nbsp;7.2(a)(i)</U>: (i) with respect to breaches of any of the representations and
warranties of (A) Seller other than the Specified Representations or (B) Buyer other than those set forth in <U>Sections&nbsp;4.1</U>,
<U>4.2(a)</U> or <U>4.5</U>, in each case, exceed the Escrow Amount, and (ii) with respect to breaches of any of (A) the Specified
Representations or (B) the representations set forth in <U>Sections&nbsp;4.1</U>, <U>4.2(a)</U> or <U>4.5</U>, in each case, exceed
the Purchase Price (the &ldquo;<U>Cap</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 7.4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Indemnification Claims</U>. (a) In order for a Buyer Indemnified Party or a Seller Indemnified Party (an &ldquo;<U>Indemnified
Party</U>&rdquo;) to be entitled to any indemnification provided for under <U>Section&nbsp;7.1</U> or <U>7.2</U> in respect of,
arising out of or involving an Action initiated or commenced by or on behalf of a Third Party (a &ldquo;<U>Third Party Claim</U>&rdquo;),
such Indemnified Party must notify, with respect to a claim for indemnification pursuant to <U>Section 7.1</U>, Seller, or, with
respect to a claim for indemnification pursuant to <U>Section 7.2</U>, Buyer (each, an &ldquo;<U>Indemnifying Party</U>&rdquo;)
in writing of the Third Party Claim (including in such notice a brief description of the applicable claim(s), including damages
sought or estimated, to the extent actually known by such Indemnified Party) within 20 Business Days after receipt by such Indemnified
Party of actual notice of the Third Party Claim; <U>provided</U>, <U>however</U>, that failure to give such notification shall
not affect the indemnification provided under <U>Section&nbsp;7.1</U> or <U>7.2</U> except to the extent the Indemnifying Party
has been actually prejudiced as a result of such failure (it being understood that the failure to have released the applicable
portion of the Escrow Amount at the expected release time due to an inability to ascertain the amount of Loss owed to a Buyer Indemnified
Party at such time shall not constitute such prejudice). The Indemnifying Party shall have the right to undertake the defense or
opposition to such Third Party Claim (at the Indemnifying Party&rsquo;s expense) with counsel selected by it and reasonably satisfactory
to the Indemnified Party so long as (i) the Indemnifying Party gives written notice to the Indemnified Party within 20 Business
Days after it has been notified of the Third Party Claim that it will defend the Indemnified Party against such Third Party Claim
and the Indemnifying Party acknowledges its obligation to indemnify the Indemnified Party for Losses related to such Third Party
Claim (subject to the Indemnity Threshold and the Cap, to the extent applicable, and the other limitations set forth herein), (ii)
the Third Party Claim involves only money damages, does not seek an injunction or other equitable relief against the Indemnified
Party and does not relate to or arise in connection with any criminal proceeding, action, indictment, allegation or investigation,
(iii) the amount claimed in such Third Party Claim, taken together with the reasonably estimated costs of defense thereof and the
claimed amount with respect to any unresolved claims for indemnification under this <U>Article&nbsp;VII</U> then pending, is (A)&nbsp;greater
than the Indemnity Threshold and (B) if applicable, less than the Cap (as reduced by any amounts previously paid by the Indemnifying
Party with respect to any resolved claims for indemnification under this <U>Article VII</U>), (iv) the Indemnified Party has not
been advised in writing by outside counsel that a legal conflict exists between the Indemnified Party and the Indemnifying Party
in connection with conducting the defense of the Third Party Claim, (v) the Third Party Claim does not allege the infringement
of the Intellectual Property Rights of any Person by the Indemnified Party and (vi) the Indemnifying Party commits in writing to
the Indemnified Party to diligently and vigorously and in good faith conduct the defense of the Third Party Claim. Neither the
Indemnified Party nor the Indemnifying Party shall settle any Third Party Claim without the prior written consent of the other
Party unless (1) the claimant in such Third Party Claim provides to such other Party an unqualified release of such other Party
from all liability in respect of such Third Party Claim, (2)&nbsp;such settlement does not involve any injunctive relief binding
upon such other Party, (3) such settlement does not encumber any of the assets of such other Party or impose any restriction or
condition that would apply to or affect such other Party or the conduct of such other Party&rsquo;s businesses and (4) such settlement
does not involve any admission of liability or wrongdoing by such other Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 62; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>In order for an Indemnified Party to be entitled to any indemnification provided for under this Agreement other than in
respect of, arising out of or involving a Third Party Claim, such Indemnified Party shall deliver notice of such claim with reasonable
promptness to the Indemnifying Party (including in such notice a brief description of the applicable claim(s), including damages
sought or estimated, to the extent actually known by such Indemnified Party); <U>provided</U>, <U>however</U>, that failure to
give such notification shall not affect the indemnification provided under <U>Section&nbsp;7.1</U> or <U>7.2</U> except to the
extent the Indemnifying Party has been actually prejudiced as a result of such failure (it being understood that the failure to
have released the applicable portion of the Escrow Amount at the expected release time due to an inability to ascertain the amount
of Loss owed to a Buyer Indemnified Party at such time shall not constitute such prejudice). If the Indemnifying Party does not
notify the Indemnified Party within 20 Business Days following its receipt of such notice that the Indemnifying Party disputes
the indemnity claimed by the Indemnified Party under <U>Section&nbsp;7.1</U> or <U>7.2</U> such indemnity claim specified by the
Indemnified Party in such notice shall be conclusively deemed a liability to be indemnified under <U>Section 7.1</U> or <U>7.2</U>
and the Indemnified Party shall be indemnified for the amount of the Losses stated in such notice to the Indemnified Party on demand
or, in the case of any notice in which the Losses (or any portion thereof) are estimated, on such later date when the amount of
such Losses (or such portion thereof) becomes finally determined, but in all cases subject to the Indemnity Threshold and the Cap,
to the extent applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 7.5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination of Indemnification</U>. (a) The obligations to indemnify and hold harmless an Indemnified Party hereto (i)
pursuant to <U>Sections 7.1(a)(i)</U> and <U>7.2(a)(i)</U>, shall terminate when the applicable representation or warranty terminates
pursuant to <U>Section&nbsp;7.5(b)</U> and (ii) pursuant to the other clauses of <U>Sections&nbsp;7.1(a)</U> and <U>7.2(a)</U>
shall terminate sixty (60) days after the expiration of any statute of limitations applicable thereto; <U>provided</U>, <U>however</U>,
that as to clause (i) above such obligation to indemnify and hold harmless shall not terminate with respect to any Losses as to
which the Indemnified Party shall have, before the expiration of the applicable period, previously made a claim by delivering a
notice of such claim to the Indemnifying Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 63; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>All representations, warranties, covenants and obligations contained in this Agreement shall survive the consummation of
the transactions contemplated by this Agreement; <U>provided</U>, <U>however</U>, that, except in the case of fraud, (i) the Specified
Representations and the representations and warranties set forth in <U>Sections&nbsp;4.1</U>, <U>4.2(a)</U> and <U>4.5</U> shall
terminate sixty (60) days after the expiration of any statute of limitations applicable thereto and (ii) the representations and
warranties contained in this Agreement other than the Specified Representations shall terminate on the date that is 18 months after
the Closing Date; <U>provided</U>, <U>further</U>, such covenants and agreements of the Parties shall survive until they are fully
performed or, if earlier, until the expiration thereof set forth in the terms of such covenants and agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 7.6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Exclusive Remedies</U>. Buyer and Seller acknowledge and agree that after the Closing, the indemnification provisions
of this <U>Article&nbsp;VII</U> shall be the sole and exclusive remedies of Buyer and Seller for any breach of the representations
or warranties or nonperformance of or default under any covenants or agreements of Buyer or Seller contained in this Agreement
or any Related Document (other than (i) claims for equitable relief, (ii) claims of, or causes of action arising from, fraud or
(iii) as expressly provided in any Related Document).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-variant: small-caps"><B>ARTICLE
VIII</B></FONT><BR>
<BR>
<B>Termination</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 8.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination</U>. This Agreement may be terminated at any time prior to the Closing:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>by the written consent of Buyer and Seller;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>by either Buyer or Seller, if:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the Closing shall not have occurred on or before April 7, 2020 (the &ldquo;<U>Outside Date</U>&rdquo;); <U>provided</U>,
<U>however</U>, that the right to terminate this Agreement under this <U>Section 8.1(b)(i)</U> shall not be available to any Party
whose failure to perform and comply with any covenant, agreement or obligation contained in this Agreement has been the primary
cause of, or primarily resulted in, the failure of the Closing to occur on or before such date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(ii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>if any Legal Restraint having the effect of restraining, enjoining or otherwise preventing the consummation of the Contemplated
Transaction shall be in effect and shall have become final and non-appealable; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(iii)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>the other Party shall have breached or failed to perform any of its representations, warranties, covenants, agreements or
obligations contained in this Agreement, and such breach or failure to perform (A) would give rise to the failure of a condition
set forth in <U>Section 6.2(a)</U> or <U>6.2(b)</U> or in <U>Section 6.3(a)</U> or <U>Section 6.3(b)</U>, as applicable, and (B)
cannot be cured by the Outside Date or, if capable of being cured by the Outside Date, has not been cured prior to the date that
is 15 days from the date that such other Party receives written notice of such breach or failure to perform.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 64; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 8.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notice of Termination</U>. In the event of termination of this Agreement by either or both of Buyer and Seller pursuant
to <U>Section 8.1</U>, written notice of such termination shall be given by the terminating Party to the other Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 8.3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Effect of Termination</U>. Notwithstanding anything to the contrary in this Agreement, in the event of termination of
this Agreement by either or both of Buyer and Seller pursuant to <U>Section 8.1</U>, this Agreement shall terminate and become
void and have no effect, and there shall be no liability or obligation on the part of any Party, other than the provisions of <U>Section
5.5</U>, <U>Section 5.13</U>, this <U>Section 8.3</U> and <U>Article IX</U>, which shall survive any such termination, and except
to the extent that such termination results from a material breach by a Party of any of its representations, warranties, covenants,
agreements, obligations or undertakings set forth in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in"><FONT STYLE="font-variant: small-caps"><B>ARTICLE
IX</B></FONT><B><BR>
<BR>
General Provisions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 9.1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Rules of Construction</U>. The Parties agree that they have been represented by counsel during the negotiation and execution
of this Agreement and have together drafted this Agreement and, therefore, waive the application of any Law, regulation, holding
or rule of construction providing that ambiguities in an agreement or other document will be construed against the Party drafting
such agreement or document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 9.2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notices</U>. All notices, requests, claims, demands and other communications hereunder shall be given (and shall be deemed
to have been duly given upon receipt) by hand delivery, by prepaid overnight courier (providing written proof of delivery), by
confirmed electronic transmission or by certified or registered mail (return receipt requested and first class postage prepaid),
addressed as follows (or at such other address for a Party as shall be specified by like notice):if to Buyer, to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Janssen Biotech, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">800 Ridgeview Drive</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Horsham, PA 19044</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Attention: President</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">with copies (which shall not constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Johnson &amp; Johnson<BR>
Law Department<BR>
One Johnson &amp; Johnson Plaza<BR>
New Brunswick, NJ 08933</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Attention: General Counsel, Pharmaceuticals<BR>
</P>

<!-- Field: Page; Sequence: 65; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Cravath, Swaine &amp; Moore LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Worldwide Plaza</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">825 Eighth Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">New York, New York 10019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 15%; padding-left: 1.5in; white-space: nowrap">Attention:</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 84%; text-align: left">Robert I. Townsend, III, Esq.</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">Jenny Hochenberg, Esq.</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">if to Seller, to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">XBiotech Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">5217 Winnebago Lane</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Austin, Texas 78744</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><BR>
Attention: John Simard</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">with a copy (which shall not constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Bryan Cave Leighton Paisner LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">120 Broadway, Suite 300</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">Santa Monica, California 90401</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in"><BR>
Attention: David G. Andersen</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>provided</U> that any notice received
at the addressee&rsquo;s location on any Business Day after 5:00 p.m. (addressee&rsquo;s local time) shall be deemed to have been
received at 9:00 a.m. (addressee&rsquo;s local time) on the next Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 9.3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Consents and Approvals</U>. For any matter under this Agreement requiring the consent or approval of either Party to
be valid and binding on the Party, such consent or approval must be in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 9.4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Counterparts</U>. This Agreement may be executed in one or more counterparts (including by electronic transmission),
all of which shall be considered one and the same agreement and shall become effective when one or more counterparts have been
signed by each of the Parties and delivered to the other Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 9.5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Entire Agreement; No Third-Party Beneficiaries</U>. This Agreement, the Escrow Agreement, the Confidentiality Agreement
and the other Related Documents constitute the entire agreement, and supersede all prior agreements and understandings, both written
and oral, among the Parties with respect to the subject matter of this Agreement, the Escrow Agreement, the Confidentiality Agreement
and the other Related Documents. Except as provided in <U>Article VII</U>, this Agreement is for the sole benefit of the Parties
and is not intended to and does not confer upon any Person other than the Parties any legal or equitable rights or remedies.</P>

<!-- Field: Page; Sequence: 66; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 9.6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Assignment</U>. Neither this Agreement nor any of the rights, interests or obligations hereunder shall be assigned, in
whole or in part, by operation of law or otherwise by either of the Parties without the prior written consent of the other Party,
and any assignment without such consent shall be null and void, except that Buyer may assign any or all of its rights and obligations
under this Agreement to any of its Affiliates without the consent of Seller.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 9.7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>GOVERNING LAW</U>. THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW
YORK, REGARDLESS OF THE LAWS THAT MIGHT OTHERWISE GOVERN UNDER APPLICABLE PRINCIPLES OF CONFLICTS OF LAWS THEREOF.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">Section 9.8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Enforcement</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Each Party irrevocably submits to the exclusive jurisdiction of (i) the state courts of New York located in New York County,
and (ii)&nbsp;the United States District Court for the Southern District of New York, for the purposes of any suit, action or other
proceeding arising out of this Agreement or the Contemplated Transactions. Each Party agrees to commence any such action, suit
or proceeding either in the United States District Court for the Southern District of New York or if such suit, action or other
proceeding may not be brought in such court for jurisdictional reasons, in the state courts of New York located in New York County.
Each Party further agrees that service of any process, summons, notice or document by the U.S. registered mail to such Party&rsquo;s
respective address set forth above shall be effective service of process for any action, suit or proceeding in New York with respect
to any matters to which it has submitted to jurisdiction in this <U>Section&nbsp;9.8</U>. Each Party irrevocably and unconditionally
waives any objection to the laying of venue of any action, suit or proceeding arising out of this Agreement or the Contemplated
Transactions in (x) the state courts of New York located in New York County, and (y) the United States District Court for the Southern
District of New York, and hereby and thereby further irrevocably and unconditionally waives and agrees not to plead or claim in
any such court that any such action, suit or proceeding brought in any such court has been brought in an inconvenient forum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="text-transform: uppercase">Each Party waives its right to trial of any issue by jury</FONT>. Each Party (i)&nbsp;certifies
that no representative, agent or attorney of the other Party has represented, expressly or otherwise, that such Party would not,
in the event of any action, suit or proceeding, seek to enforce the foregoing waiver and (ii)&nbsp;acknowledges that it and the
other Party has been induced to enter into this Agreement, by, among other things, the mutual waiver and certifications in this
<U>Section 9.8(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Parties agree that irreparable damage would occur and that the Parties would not have any adequate remedy at law in
the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise
breached. It is accordingly agreed that the Parties shall be entitled to an injunction or injunctions to prevent breaches of this
Agreement and to enforce specifically the terms and provisions of this Agreement in the state courts of New York located in New
York County, and the United States District Court for the Southern District of New York, this being in addition to any other remedy
to which they are entitled at law or in equity and as further set forth in this <U>Section&nbsp;9.8</U>. For the avoidance of doubt,
this <U>Section 9.8(c)</U> shall not restrict any Party from asserting that the terms and provisions of this Agreement have not
been breached (or would not be breached) by the actions or omissions (or intended actions or omissions) of such Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 67; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 9.9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Severability</U>. If any term or other provision of this Agreement or any Related Document is invalid, illegal or incapable
of being enforced by any rule of law or public policy, all other conditions and provisions of this Agreement or such Related Document
shall nevertheless remain in full force and effect. Upon such determination that any term or other provision is invalid, illegal
or incapable of being enforced, the Parties shall negotiate in good faith to modify this Agreement or such Related Document so
as to effect the original intent of the Parties as closely as possible to the fullest extent permitted by applicable Law in an
acceptable manner to the end that the transactions contemplated hereby are fulfilled to the extent possible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Section 9.10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Amendment; Waiver</U>. No modification, amendment or waiver of any provision of this Agreement shall be effective unless
it is in writing and signed by the Party against whom enforcement of any such modification, amendment or waiver is sought. No action
taken pursuant to this Agreement, including any investigation by or on behalf of either Party, shall be deemed to constitute a
waiver by the Party taking such action of compliance by the other Party with any representation, warranty, covenant, agreement
or obligation contained herein. The waiver by either Party of a breach of any provision of this Agreement shall not operate or
be construed as a further or continuing waiver of such breach or as a waiver of any other or subsequent breach. Neither the failure
of either Party to enforce, nor the delay of either Party in enforcing, any condition or part of this Agreement at any time shall
be construed as a waiver of that condition or part or forfeit any rights to future enforcement thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Remainder of page intentionally left
blank]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 68; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; padding-top: 12pt; padding-bottom: 6pt; border-bottom: Black 4pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, the Parties have caused
this Agreement to be signed by their respective officers hereunto duly authorized, all as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-transform: uppercase">SELLER:</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-transform: uppercase">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-transform: uppercase; text-align: left">XBIOTECH INC.</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="text-transform: uppercase; width: 5%">&nbsp;</TD>
    <TD STYLE="width: 45%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="text-transform: uppercase">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="text-transform: uppercase">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ John Simard</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name:  John Simard</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title: President &amp; CEO</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">BUYER:</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-variant: small-caps; text-transform: uppercase; text-align: left">JANSSEN BIOTECH, INC.</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Marti Heckman</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Name: Marti Heckman</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Title: Vice President</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Signature Page to Asset Purchase Agreement]</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
